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Brain arteriovenous malformations 
(AVM) are rare vascular anomalies in 
which the cerebral arteries and veins 
are connected without the normal 
intervening capillary bed. Most often, in 
roughly half of the cases, the event leading 
to diagnosis is intracranial hemorrhage. 
The second most common symptom 
is a focal epileptic seizure, leading to 
diagnosis in one-third of the cases. AVM 
incidence in the general population is 
approximately 1/100,000 person-years. 
The average age for AVM diagnosis 
is slightly over 30 years, meaning that 
the disease often affects working-age 
people. It is also a significant cause of 
intracranial hemorrhage in children and 
young adults. The AVM hemorrhage is 
lethal in, on average, 5–25% of patients. 
In this thesis we have studied patients 
in the Helsinki AVM database using the 
15D health-related quality of life (HRQoL) 
instrument and questionnaire data about 
lifestyle. Our database consists of 805 
AVM patients treated in the Helsinki 
University Hospital Department of 
Neurosurgery between 1942 and 2014. 
Of them, 325 patients answered the 
mailed questionnaire sent in 2016 and 
comprise the study cohort of this thesis. 
Our research revealed that after a mean 
17.6 years (SD ±12.0 yr) of follow-up the 
HRQoL of treated AVM patients in general 
was, when considering the difficulty of the 
disease, only modestly decreased. Also, 
most of the patients had been able to 
return to work. In the multivariate model, 
the decreased HRQoL of AVM patients 
was explained by older age, sex (being 
female), difficult refractory epilepsy, 
difficult location or structure of the AVM, 
and more than one hemorrhagic episode. 
Our results support active AVM treatment 
in those cases which the procedure can be 
done safely and the treatment-related risks 
do not exceed the estimated cumulative 
rupture risk. Another novel finding from 
our study cohort was that the prevalence of 
smokers was significantly higher in AVM 
patients when compared to a matched 
general population. The high prevalence, 
especially during the diagnosis, inspires 
more vigorous investigation of the role 
of cigarette smoking in the currently 
unknown etiology of AVMs. With our 
final article, we participated in the 
on-going discussion in the scientific 
community about the statistical handling 
of the commonly used functional outcome 
instrument, the modified Rankin Scale. 
We showed, using our AVM patient cohort, 
that the popular dichotomous approach 
in outcome assessment could significantly 




mat (AVM) ovat harvinaisia verisuoni-
epämuodostumia, joissa aivovaltimot 
ja -laskimot ovat yhdistyneet ilman nor-
maalia hiussuoniverkostoa. Diagnoosiin 
useimmiten, noin puolessa tapauksista, 
johtava syy on aivoverenvuoto. Toiseksi 
yleisimmin diagnoosiin johtaa epilepti-
nen kohtaus, noin kolmanneksella poti-
laista. AVM:ien ilmaantuvuus väestössä 
on keskimäärin 1/100 000 henkilövuot-
ta. Keskimäärin AVM diagnosoidaan hie-
man yli 30-vuotiailla. Sairaus koskettaa-
kin usein työikäisiä ja se on yksi merkit-
tävistä lasten ja nuorten aikuisten aivo-
verenvuodon aiheuttajista. Potilaista, joil-
la AVM puhkeaa, aivoverenvuoto johtaa 
kuolemaan noin 5–25%:ssa tapauksista. 
Tässä väitöskirjatyössä on tutkittu 
Helsinki AVM -aineiston potilaita käyttä-
en 15D-elämänlaatumittaria ja kyselykir-
jeitse saatua dataa liittyen potilaiden elin-
tapoihin. Tietokantaamme on kerätty vuo-
sina 1942–2014 Helsingin yliopistollisen 
sairaalan Neurokirurgian klinikassa hoi-
detut AVM-potilaat (n=805). Heistä 325 
vastasi vuonna 2016 lähetettyyn elämän-
laatukyselykirjeeseen ja muodostaa tämän 
väitöskirjan päätutkimuskohortin. Tutki-
muksemme paljasti, että keskimäärin 17.6 
vuoden (SD=±12.0v) seuranta-ajan jälkeen 
hoidettujen AVM-potilaiden elämänlaatu 
oli, ottaen huomioon taudin vaikeusas-
teen, ainoastaan maltillisesti madaltunut. 
Lisäksi, suurin osa potilaista oli kyennyt 
palaamaan työelämään. Monimuuttuja-
mallissa heikentynyttä elämänlaatua selit-
täviä tekijöitä AVM-potilaiden välillä olivat 
vanhempi ikä, naissuku puoli, vaikea jään-
nösepilepsia, AVM:n vaikea anatominen 
sijainti tai rakenne, ja useampi kuin yk-
si aivoverenvuoto. Tutkimustuloksemme 
kannustavat AVM:n aktiiviseen hoitoon 
niissä tapauksissa, joissa toimen pide voi-
daan suorittaa turvallisesti, eivätkä toimen-
piteen riskit ylitä arvioitua elinaikana ker-
tyvää vuotoriskiä. Toinen uusi löydös tut-
kimuskohortistamme oli, että tupakoivien 
AVM-potilaiden esiintyvyys on huomatta-
vasti korkeampi kuin tupakoijien osuus 
suomalaisessa verrokki väestössä. Erityi-
sesti tupakoijien suuri määrä AVM:n diag-
noosivaiheessa kannustaa tutkimaan tu-
pakoinnin osuutta AVM:ien nyky hetkellä 
tuntemattomassa etiologiassa. Lopulta, 
otimme tutkimuksellamme kantaa tiede-
yhteisössä käytävään keskusteluun yleises-
ti käytetyn modified Rankin Scale -luoki-
tuksen tilastollisesta käsittelystä. Osoitim-
me käyttämällä AVM-potilailtamme saa-
tua 15D-elämänlaatudataa, että tutkimuk-
sissa usein käytetty kahtiajakoon pohjau-
tuva luokittelu saattaa merkittävästi vääris-
tää tutkimustuloksia.
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1 INTRODUCTION
1.1 Brain arteriovenous 
malformations
Brain arteriovenous malformations 
(AVMs) are rare vascular anomalies of 
unknown etiology. Owing to their complex 
neurovascular anatomy, they are one of 
the most difficult neurosurgical diseases 
to manage. AVM consists of a tangle of 
vessels called a nidus, with abnormal 
connections between the arteries and 
veins without a capillary network in 
between.1 AVMs are most often detected 
with rupture; however, epileptic seizures 
or a neurological deficit might also lead to 
diagnosis.2 The intracranial hemorrhage 
caused by AVM rupture is associated with 
significant mortality and morbidity.3 This 
is especially distressing since the patients 
are mostly working-age, young adults 
and children.4 Considering the young age 
of AVM patients, it is often meaningful 
to try eliminating the risk of AVM 
rupture altogether with interventional 
treatment.5 However, the risks related to 
the procedure itself are also notable. They 
can pose too large a risk of complications 
and therefore some AVMs can only be 
observed.6 Fortunately, novel medical 
therapies are being developed and this 
noninvasive approach might revolutionize 
the treatment of AVMs in the future.7 
1.2 Helsinki AVM database
The Helsinki AVM database has been 
collected retrospectively from medical 
records and images. It consists of all 
AVM patients in the Helsinki University 
Hospital (HUH) catchment area who 
were treated between 1942 and 2014 in 
our neurosurgical clinic. At the time 
of working on this thesis, the database 
consisted of 805 patients. In 2016, 
questionnaire letters were sent to all adult 
patients in the database. These letters 
included a separate panel of questions 
regarding self-sufficiency and lifestyle, 
and the 15D health-related quality of 
life (HRQoL) questionnaire. The patients 
who returned the questionnaire were 
collected into a HRQoL database, which 
consists of 325 living adult AVM patients. 
The patients in this database were the 
main study population of this thesis 
project
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2 REVIEW OF THE LITERATURE
2.1 Brain arteriovenous 
malformations
2.1.1 Anatomy
AVMs are rare vascular anomalies located 
inside the cranium. They are made of an 
abnormal collection of vessels where a 
draining vein receives oxygenated blood 
from a feeder artery without the normal 
interposed capillary beds. The blood flow 
goes through a tangle of blood vessels, 
called a nidus (Figure 1).1 The nidus 
consists of direct connections between 
the arterial and the venous side which 
act as high-flow shunts wherein the 
medium-to-high pressure arterial blood 
flowing to the draining veins creates 
a risk of rupture. An AVM rupture 
leads to an intracerebral hemorrhage 
(ICH), subarachnoid hemorrhage 
(SAH), intraventricular hemorrhage 
(IVH), subdural hemorrhage (SDH) 
or a combination of these.8 The most 
common type is ICH, accounting for 
approximately 80% of the ruptures.9 
AVMs can be classified based on their 
anatomical characteristics. These 
classifications can be used to estimate 
the rupture risk of the lesion, the 
anticipated treatment effect, and the 
short- and long-term outcomes, and are 
vital in the preoperative understanding 
of the topography and angioarchitecture. 
Topographically, AVMs are classified as 
either telencephalic (so-called cortical 
AVMs, 72% of the lesions), subcortical 
(2%), or deep / central AVMs (26%).1 The 
most common type, the cortical AVMs, 
can be located in the sulci (28%), gyri 
(12%) or mixed sulco-gyrally (29%).1 In 
addition to this, location in regard to the 
tentorium determines whether AVM is 
supratentorial (86%) or infratentorial 
(14%).10, 11 The eloquence is another 
determining factor  of location. Eloquent 
locations include the functionally 
important structures of the cerebral 
lobe and the vitally important structures 
such as the brainstem and midbrain. 
The feeding arteries can be subdivided 
into several categories depending on 
their origin. Generally speaking, the 
superficial arteries are often easier to 
occlude during surgery, whereas the 
feeders from perforator arteries can 
create significant challenges.12 Venous 
drainage can be subdivided into deep or 
superficial draining, depending on the 
location of the veins involved in the nidus. 
Superficial drainage through the cortical 
Figure 1. A schematic illustration of a cortical 
brain AVM.
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veins often drains into the adjacent dural 
sinus, whereas deep AVMs drain into the 
subependymal venous system. The size 
of the AVM is determined by the size of 
the nidus and can vary from a couple 
of millimeters to multiple centimeters 
wide. In around 7% of cases, there is 
an associated flow-related aneurysm, a 
pouch-like widening of an artery, located 
near the AVM commonly in the feeder 
artery.13
2.1.2 Development and 
pathophysiology
AVMs are classically viewed as congenital 
lesions which develop prenatally and 
in most cases remain silent until they 
become symptomatic, usually by the 
third or fourth decade of the patient’s 
life.14, 15 This view has been questioned 
with an increasing number of de novo 
AVMs reported and novel discoveries of 
the genetics behind the etiology.7, 11, 16, 17 
Furthermore, very few reports of prenatal 
AVMs exist,18-20 and the diagnosis remains 
extremely rare during the first years after 
birth.21, 22 Although there is an increasing 
body of evidence about the molecular 
mechanisms and genetics behind sporadic 
AVMs, the exact pathogenesis remains 
mostly unknown.7, 23-26 Dysfunction of 
the cerebrovascular endothelium and the 
angiogenic pathways seem to play a major 
role in the formation based on current 
knowledge.7, 27 
Figure 2. Intraoperative picture of a cortical brain AVM.
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2.1.2.1 Related diseases 
An autosomal dominantly inherited 
condition, Osler-Weber-Rendu syndrome 
or hereditary hemorrhagic telangiectasia 
(HHT), significantly increases the risk 
of developing AVMs.28 In HHT this is 
caused by loss-of-function mutations 
in genes which encode the proteins 
mediating TGF-β signaling.29, 30 HHT 
patients form a minority of AVM patients, 
as about 95% of AVMs are sporadic.24, 31 
Another closely related etiology, dural 
arteriovenous fistulae (DAVF), shares 
the same anatomic features as AVMs, 
with an arteriovenous shunt without an 
intervening capillary bed. The shunt, 
between meningeal arteries and dural 
sinus and/or cortical veins, is usually 
contained inside the leaflets of the dura 
mater, compared to AVMs which are 
inside the pia mater.32  Most DAVFs 
in adulthood are acquired, and  for a 
proportion of patients the etiology can 
be tracked down to a specific event 
(e.g., traumatic head injury, previous 
craniotomy, tumor or dural sinus 
thrombosis).33, 34 A similar relationship 
has not been found in AVM patients. The 
formation of DAVFs is proposed to be 
related to either progressive stenosis or 
occlusion of dural venous sinuses, which 
leads to an increase in sinus venous 
pressure which in turn triggers the 
development of the fistulous connections 
between the meningeal arteries and 
the dural sinus or cortical veins.34 This 
theory is supported by the finding of a 
correlation between DAVF patients and 
inherited thrombotic diseases, such as 
Factor V Leiden or protein C deficiency.34, 
35 Again, similar connections have not 
been reported in AVM patients.
2.1.2.2 Introduction to angiogenesis 
and the two-hit theory
During embryogenesis the brain 
vasculature is formed de novo from 
endothelial precursor cells, angioblasts, 
in a process called vasculogenesis.36 After 
this, new blood vessels are formed from 
the pre-existing ones in angiogenesis.37 
Angiogenesis is also present after the 
developmental phases, postnatally, in 
many physiological processes such as 
wound healing and granulation tissue 
formation, and in pathological processes 
in which, for instance, a malignant 
tumor can create neovascularization to 
gain nutrients and oxygen.38 After birth 
there are several angiogenic growth 
factors which control the changes in the 
body’s vasculature by stimulating blood 
vessel formation and growth.39 One of the 
most important angiogenic factors in the 
human brain is the vascular endothelial 
growth factor (VEGF).36, 40 In addition, 
a number of inhibiting factors and 
extracellular proteins are involved in the 
cascade of physiological angiogenesis.39 
TGF-β, VEGF and many other growth 
factors, as well as signaling cascades 
such as NOTCH and RAS/MAPK/ERK, 
are involved in the regulation of target 
gene expression, and when mutated 
cannot up- or downregulate the desired 
genes.41-43 These play a major role in the 
arteriovenous specification, and together 
with the downstream transcription 
factors and the external mutagens 
create the fundamentals behind the 
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pathophysiology of AVMs.27, 44 A recent 
breakthrough in the research of sporadic 
AVMs was the finding of AVM endothelial 
cells having somatic mutations in KRAS, 
a proto-oncogene part of the Ras family 
of proteins associated with cell growth 
and proliferation.7 This specific study 
also illustrated increased MAPK-ERK 
signaling in the samples without the 
KRAS variants, which the researchers 
concluded might delineate the 
importance of the MAPK-ERK pathway 
in AVM formation.7 
General theories about the formation 
of brain vascular anomalies have been 
proposed. One of them suggests a two-
hit theory, originally developed in cancer 
research, but which applies to many other 
diseases as well.44 A rather simplified 
version of the theory proposes the first 
hit, a mutation, enables the pathological 
reactivation of pathways involved in 
cellular proliferation, apoptosis and 
abnormal tissue formation. However, we 
are constantly battling somatic mutations 
around our bodies, which is why the 
second hit is needed to keep the mutated 
pathways activated. The second hit adjusts 
the microenvironment by promoting 
cellular proliferation, differentiation 
and migration. The hit can be either 
another mutation which sustains the 
proinflammatory, promigratory and 
proliferative stimuli, or an external 
mutagen which maintains this abnormal 
microenvironment (Figure 3).44 
2.1.3 Patient characteristics 
and epidemiology
AVMs often impair young patients in 
their third or fourth decade of life.9, 45 
However, many live asymptomatically 
Figure 3. Illustration of the 
scheme behind the two-hit 
theory. The cascade begins 
with a first hit promoting a 
mutation to a key regulatory 
gene; however, this alone can 
be controlled by different 
cellular mechanisms and 
homeostasis is sustained. If, 
however, there is another key 
mutation or the pathogenic 
microenvironment is sustained 
by external factors, the second 
hit is able to destabilize 
the homeostasis and a 
malformation can develop.
18
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without ever getting the diagnosis, 
which understandably complicates 
the prevalence determination.46 The 
prevalence might be up to 0.2%,4, 31 
whereas patients with a confirmed AVM 
diagnosis only make-up 0.02% of the 
population.12 The current incidence of 
AVMs is around 1/100,000 person-years, 
however, the incidence will supposedly 
slightly increase owing to more extensive 
imaging.9, 46 AVM hemorrhages account 
for roughly 4% of all non-traumatic 
strokes.47 Owing to their peak prevalence 
in the early decades of life, they account 
for one-third of all hemorrhagic strokes 
in young adults and by some estimates 
even half of the hemorrhagic strokes 
in children.47–49 In our own database, 
there is a slight predominance of male 
patients compared to females, however, 
in the existing literature the distribution 
is equal.47 (Figure 4). 
2.1.4 Symptoms and diagnosis
AVMs most commonly present with 
ICH.45, 50 AVM patients are typically 
younger than patients with other types 
of ICH – in a massive study consisting 
of 630,969 hospitalizations for ICH from 
2002 to 2011 in the United States the 
mean age between AVM patients and 
other causes for ICH were 52 and 72 
years, respectively.51 In the same study, 
there was a slight male predominance, 
with 52.5% males versus 49.3% in other 
causes for ICH.51 The other presenting 
symptoms of AVM patients are epileptic 
seizures, focal neurological deficits, 
headache, as well as other types of 
intracranial hemorrhages.52 Epileptic 
seizures are more common in AVM 
patients than with other causes of ICH.51 
The symptomatology depends on 
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Figure 4. Age distribution at diagnosis of AVM based on our AVM database of 805 AVM patients.  
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supratentorial and infratentorial 
lesions present with a slightly different 
pattern of symptoms. Curiously, some 
patients’ brains adapt to the altered 
vascular environment and can remain 
asymptomatic, whereas some develop 
difficult symptoms owing to hemodynamic 
changes in the parenchyma.31 Yet, the most 
common cause for diagnosis in both groups 
is still a hemorrhagic stroke (Figure 5).9 
AVMs used to mainly be diagnosed because 
of the rupture, but owing to changes in 
diagnostics, increasing numbers of AVMs 
are diagnosed unruptured.2, 53 Small AVMs 
tend to be diagnosed incidentally or when 
ruptured compared to larger AVMs.54 This 
is partly because small AVMs do not 
become symptomatic as easily as the larger 
ones. AVM diagnosis is often verified with 
digital subtraction angiography (DSA) 
or magnetic resonance angiography 
(MRA), however, the first indication of 
a lesion can be noticed with the more 
conventional computed topography (CT) 
or magnetic resonance imaging (MRI).31 
DSA is needed before the treatment, as 
it provides the most accurate topography 
of the lesion. Figure 6 illustrates different 
imaging modalities from the same patient, 
diagnosed with a ruptured infratentorial 
AVM.
2.1.4.1 Epilepsy 
An epileptic seizure is the second 
most common symptom leading to 
AVM diagnosis.14 Of the patients who 
present with an epileptic seizure, on 
average 60% develop epilepsy within 
the next 5 years if untreated.55 Epilepsy 
independently is also another factor 
associated with decreased quality of life 
(QoL).56 Sometimes seizure-freedom 
can be met with resection of the AVM, 
however, drug-resistant epilepsy alone is 
rarely the only indication for surgery.56 






Figure 5. The distribution of symptoms in 805 AVM patients in our database. Severe headache and sudden loss of 
consciousness were the most common symptoms, reflecting the tendency of AVMs to bleed during initial diagnosis.  
 
 
The symptomatology depends on the location of the lesion, and therefore supratentorial and 
infratentorial lesions present with a slightly different pattern of symptoms. Curiously, some patients’ 
brains adapt to the altered vascular environment and can remain asymptomatic, whereas some 
develop difficult symptoms owing to hemodynamic changes in the parenchyma.31 Yet, the most 
common cause for diagnosis in both groups is still a hemorrhagic stroke (Figure 5).9 AVMs used to 
mainly be diagnosed because of the rupture, but owing to changes in diagnostics, increasing numbers 
of AVM  are diagnosed unruptured.2, 53 Small AVMs tend to be diagnosed incidentally or when 
ruptured compared to larger AVMs.54 This is partly because small AVMs do not become symptomatic 
as easily as the larger ones. AVM diagnosis is often verified with digital subtraction angiography (DSA) 
or magnetic resonance angiography (MRA), however, the first indication of a lesion can be noticed 
with the more conventional computed topography (CT) or magnetic resonance imaging (MRI).31 DSA 
is needed before the treatment, as it provides the most accurate topography of the lesion. Figure 6 
illustrates different imaging modalities from the same patient, diagnosed with a ruptured 
infratentorial AVM. 
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Figure 5. The distribution of symptoms in 805 AVM patients in our database. Severe headache and 
sudden loss of consciousness were the most common symptoms, reflecting the tendency of AVMs 
to bleed during initial diagnosis.
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Figure 6A (left): Preoperative CT image (axial-
plane) showing a right-sided infratentorial ICH. 
Figure 6A (right): Preoperative MRI image 
(axial-plane, T2 sequence) from the same 
patient. The cerebellar AVM is better visualized.
Figure 6B (left): Preoperative 3D rotational DSA 
(anterior-posterior view) of the patient in Figure 
6A. An infratentorial, right-sided AVM draining 
to the adjacent sinus is presented.
Figure 6B (right): Preoperative DSA, color-
coded according to flow delay / transit time for 
the contrast agent. The premature drainage into 
the sinus on the AVM side can be distinguished 
by the green color of the right-sided transverse 
sinus, compared to the normal blue-colored 
sinus on the left-side.
been associated with improvement in 
social adjustment and occupational 
integration.57 Despite being symptom-
free most of the time, having epilepsy can 
reduce the person’s QoL on many levels.56 
Examples of this are driving restrictions 
and social stigmas, which are both 
associated with the inability to continue 
a premorbid lifestyle.56 Additionally, 
the psychological strain of the disease 
might independently decrease a person’s 
everyday performance level.58 In addition 
to this, the prevalence of patients with 
neurobehavioral disorders, such as 
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cognitive or behavioral disorders, is 
higher among patients with epilepsy, and 
these have shown connection to reduced 
HRQoL.59
2.1.5 Natural history
Natural history studies aim to investigate 
the natural course of the disease, the course 
from the pathological onset until either 
recovery or death. To make treatment 
decisions, clinicians and patients need to 
understand the natural course, because 
this is weighed against the risks related 
to treatment. The rarity of AVMs and the 
usual hemorrhagic presentation have 
complicated how AVM natural history 
studies are conducted because, with 
modern knowledge, patients presenting 
with a ruptured lesion are often treated, 
thus the real natural history is ended. 
However, there are some historical 
AVM patient-series with only minimal 
selection bias, from which AVM natural 
history estimates have been published.45, 
52, 60 In the following sections, I cover the 
risk of AVM hemorrhage and excess 
mortality first based on the Helsinki 
natural history series,45, 52, 61 and later the 
series from other research groups.
2.1.5.1 Rupture risk in theory
The risk of AVM hemorrhage is highly 
dependent on multiple factors and 
depends on the time when the risk is 
assessed. Two different lesions can 
harbor a very different annual rupture risk 
depending on various characteristics. The 
theoretical risk is cumulative by nature. If 
we assume the annual risk of hemorrhage 
stays the same for one individual (what 
we actually know is not the case), then 
we can estimate the cumulative rupture 
risk c for the supposed lifetime with the 
formula c = 100% * (1 – (1 – p)t), where p 
is the annual probability of hemorrhage 
and t is the time at risk in years.62 The 
Figure 7. c = 100% * (1 – (1 – p)
t), 
cumulative rupture risk c for the 
supposed lifetime where p is the 
annual probability of hemorrhage 
and t is the time at risk in years. 
It is assumed that the theoretical 
annual rupture risk stays constant. 
The increase in cumulative 
probability/risk is highest during 
the first years after diagnosis also 
theoretically. Note: despite high 
cumulative probability on the 
purple curve, the theoretical risk 
will never reach 100%.
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theoretical increase in the risk is the 
highest during the first years after the 
beginning of calculation, and the curve 
flattens as time progresses. Clinically, 
the cumulative nature means that for 
young AVM patients even if their yearly 
rupture risk was small, say 1–2%/year at 
diagnosis, because of the life-expectancy 
of several decades, the risk increases to a 
significant figure even before they retire. 
This theoretical nature of cumulative 
rupture risk is illustrated in Figure 7. 
What we know from the literature is 
that the annual rupture rate does seem 
to be the highest during the first years 
after diagnosis and decreases in follow-
up. This phenomenon has been reported 
by many researchers.45, 60, 63, 64 One reason 
behind this could be that the AVMs which 
become symptomatic might experience 
changes in the hemodynamics in the 
lesion and adjacent brain regions and 
this could be indicating a near-future 
rupture. 
Finally, an often-confusing aspect in risk 
factor studies is the differing associations of 
risk factors for ‘’hemorrhagic presentation’’ 
and for ‘’future hemorrhage’’. For example, 
small AVM size has been associated with 
hemorrhagic presentation, however, large 
AVM size has been associated with future 
hemorrhage.54, 65 This seems confusing 
but could at least partly be explained by 
the fact that small AVMs cause symptoms 
proportionally more seldom than large 
AVMs. This leads to the bias that small 
AVMs are more often diagnosed when 
ruptured (Figure 8), even though small 
size itself is not a true risk factor for AVM 
hemorrhage.45 This ‘’over-presentation’’ 
with hemorrhage can influence rupture 
risk studies and is an important factor 
to consider when conducting statistical 
tests, for example. The true risk factors for 
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Figure 8: Schematic illustration about the 
phenomenon leading to small size often being 
associated with hemorrhagic presentation, even 
though it is not a true risk factor for rupture. 
Because small AVMs tend to cause symptoms 
proportionally less often than larger AVMs, it 
appears that they are associated with hemorrhagic 
presentation. Note: we do not know the exact 
number of undiagnosed AVMs, as some might 
remain asymptomatic for a whole lifetime. 
Supposedly, small AVMs remain asymptomatic 








Figure 8. Schematic illustration about the 
phenomenon leading to small size often being 
associated with hemorrhagic presentation, 
even though it is not a true risk factor for 
rupture. Because small AVMs tend to cause 
symptoms proportionally less often than larger 
AVMs, it appears that they are associated with 
hemorrhagic presentation. Note: we do not 
know the exact number of undiagnosed AVMs, 
as some might remain asymptomatic for a 
whole lifetime. Supposedly, small AVMs remain 
asymptomatic more often than larger AVMs.
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2.1.5.2 The Helsinki series
The Helsinki AVM database introduced 
in section 1.2 includes patients treated 
in the Department of Neurosurgery at 
HUH from 1942 onward. The department 
was the only neurosurgical department 
in Finland until the late 1960s. At the 
time the natural history studies were 
conducted, the catchment area of HUH 
was around 2 million citizens.45 Owing 
to the Finnish public healthcare system, 
all Finnish AVM patients are treated in 
university hospitals. The data related to 
the patient and treatment are registered 
in electronic patient registries, which are 
easily accessible for retrospective data 
collection. Also, Finns are genetically 
a relatively homogenous population, 
which makes Finland an ideal country 
for epidemiological studies. 
2.1.5.2.1 Risk factors for AVM 
hemorrhage
The Helsinki natural history series 
rupture risk study included 238 patients 
admitted between 1942 and 2005 with 
at least 1 month of hemorrhage- and 
treatment-free follow-up time (mean 
follow-up time of 13.5 years). During the 
3222 person-years of follow-up, there were 
77 hemorrhages, concluding an overall 
2.4% rupture rate.45 Demonstrating 
the phenomenon discussed earlier, the 
annual rupture rate was the highest during 
the first few years after the diagnosis, and 
for the whole patient cohort this meant 
a 4.7% annual rupture rate during the 
first 5 years after diagnosis and a 1.6% 
annual rate afterward, translating into 
the average 2.4% annual rupture risk 
during the whole follow-up time.45 This 
is comparable to a meta-analysis of 
untreated brain AVMs in 2525 patients 
during 6074 patient-years of follow-
up, in which the overall annual rate of 
hemorrhage was 2.3% (95% confidence 
interval (CI): 2.0–2.7) for the following 10 
years after initial diagnosis.66 There was 
an overall 21% (95% CI: 12–27%) 5-year 
rupture rate and a 39% (95% CI: 32–47%) 
20-year rupture rate after admission.45 
However, as mentioned, the risk 
varies between patients and depends on 
multiple factors, presented in Table 1. 
Similarly, as with the rupture rates the 
risk factors possess a different behavior 
in the statistical models according to 
the time period evaluated, meaning that 
for example a certain characteristic can 
increase the rupture risk in the first five 
years of follow-up but then not after. This is 
partly explained by the effect certain AVM 
features and patient characteristics have on 
the treatment decisions and outcome. For 
example, more easily treatable lesions can 
lead to exclusion from the cohort (=end of 
natural history) earlier than more difficult 
lesions, which are carefully observed rather 
than interventionally treated. Referring 
to the Helsinki natural history study, 
according to the multivariate proportional 
hazard models, the independent risk 
factors for rupture during the whole 
follow-up period (mean 13.5 years, range: 
1 month to 53.1 years) were a previous 
rupture, large size (>5cm in diameter), 
and deep and infratentorial location (Table 
1).45 These factors are also supported by 
other natural history studies.65-68 Another 
interesting finding (from Model 3, 
not illustrated in Table 1) was that the 
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combination of deep location and previous 
rupture increased the relative risk (RR) up 
to 4.21 (95% CI: 1.19–14.9).45 Additionally, 
exclusively deep venous drainage was 
another significant risk factor increasing 
the rupture rate, however, only during the 
first 5 years after diagnosis. This increase 
in rupture rates was significant only in the 
univariate Kaplan–Meier curves, which 
demonstrated a 34% (95% CI: 20–48%) 
cumulative rupture rate during the first 5 
years, compared to 20% (95% CI: 12–28%) 
for cortical drainage and 5% (95% CI=0–
13%) for cortical and deep drainage.45 
From the univariate Kaplan–Meier curves, 
the largest increase in the rupture rates 
was with an infratentorial location during 
the first 5 years after diagnosis, when the 
Table 1. RR5 = relative risk in the first 5 years after diagnosis, RRO = relative risk during the whole 
period. Models were created with Cox regression analyses, with the following differences: Model 1 
included all the tested variables and did not include the interactions between the tested variables 
and excluded the non-significant variables using a stepwise procedure; Model 2 included all the 
variables without exclusion and calculated adjusted RRs for all of them; and Model 3 used the 
stepwise procedure and also included the interactions between the variables (except the interactions 
between age and sex). Model 3 did not produce significant risk factors for the first 5 years and 
is not therefore included in the RR5 column. The table is adapted from Hernesniemi JA, Dashti R, 
Juvela S, Vaart K, Niemela M, Laakso A. Natural history of brain arteriovenous malformations: a long-
term follow-up study of risk of hemorrhage in 238 patients. Neurosurgery. 2008;63(5):823-831.
RR5* (95%-CI) RRO (95%-CI)





































































‡ indicates statistical significance, 2-tailed p<0.05. 
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factor was associated with an 11.6% annual 
rupture rate, followed by deep location 
(8.9%) and deep venous drainage (8.1%). 
Other natural history studies have also 
recognized infratentorial location as a 
risk factor for hemorrhage, even though 
it does not always remain significant 
in the multivariate models.64, 65 Finally, 
patients who experienced hemorrhage 
(29.3y±1.4y) were younger during 
admission than patients with no rupture 
(34.4y±15.1y).45 However, controversy exists 
since increasing age has been found as 
a predictor of subsequent hemorrhage 
by others.65 Results about hemorrhagic 
presentation are also contradicting, with 
some finding increasing age66 and some 
younger age predictive.69 Despite the lack 
of general agreement on the risk factors for 
hemorrhage, it is generally acknowledged 
that factors whose absence should protect 
the patient from rupture have been 
recognized.70
2.1.5.2.2 Excess mortality
The diagnosis of AVM is associated 
with a significant excess mortality in 
long-term follow-up compared with the 
general population of Finland.61 This 
finding is from a natural history study 
of 623 Finnish AVM patients with a total 
of 10,165 person-years of follow-up. The 
mortality is highest during the first year 
after diagnosis and decreases slightly 
after but remains elevated in the long-
term owing to its cumulative nature.61 
The increase in the first years after 
diagnosis is understandable, as this is the 
time when treatment- and hemorrhage-
related mortality is highest.61 However, 
even after 20 years AVM-related deaths 
constituted approximately half of the 
causes of death in the study cohort. 
Women experienced more AVM-related 
deaths compared to men (60% vs. 
43%), who had a higher proportion of 
cardiovascular disease (11% vs. 20%) and 
trauma and other disease (11% vs. 25%) 
as a cause of death.61 Mean age at an 
AVM-related death was 43.2 years (SD: 
±17.9y). Men had also a higher excess 
mortality, even though there were no 
significant differences with respect to 
age, lesion characteristics, proportion of 
hemorrhagic presentation, treatment or 
length of follow-up compared to women. 
Compared to the general population, men 
experienced significant excess mortality 
with cumulative relative survival ratio 
(CRSR) of 0.89 (95% CI: 0.84–0.92) after 
5 years, a CRSR of 0.70 (0.64–0.76) after 
20 years and a CRSR of 0.58 (0.48–0.65) 
after 30 years, compared to women with 
CRSRs of 0.92 (0.88–0.95), 0.87 (0.79–
0.94) and 0.85 (0.74–0.95), respectively. 
Surprisingly, AVM rupture during 
admission did not significantly increase 
the mortality compared to unruptured 
AVMs in the long-term, rather the 
effect of successful treatment was 
more meaningful in preventing excess 
mortality. Interestingly, partial occlusion 
also started showing a favorable effect 
after 5–7 years of follow-up compared to 
untreated AVMs.61 Patients whose AVM 
was unruptured and totally occluded 
with treatment had the best outcome 
regarding excess mortality, with only 
1.9% excess mortality during the first 
year after diagnosis (RSR 0.98, 95% 
CI: 0.92–1.00), and after the first year 
there were no statistically significant 
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differences in excess mortality compared 
to the general population.61 Patients with 
ruptured AVMs that were totally occluded 
with treatment had 3.3% excess mortality 
during the first year, and a 10-year CRSR 
of 0.94 (95% CI: 0.89–0.97) and a 30-year 
CRSR of 0.90 (95% CI: 0.77–0.99). In 
comparison, the respective numbers 
for conservatively treated patients were 
CRSR 0.72 (0.63–0.79) and 0.49 (0.38–
0.59).61
2.1.5.3 ARUBA and other series
A comparable figure to the Helsinki 
series yearly rupture rate was found in 
a meta-analysis of untreated brain AVMs 
in 2525 patients during 6074 patient-
years of follow-up, in which the overall 
annual rate of hemorrhage was 2.3% 
(95% CI: 2.0–2.7) for the 10 years after 
initial diagnosis.66 The rate was higher 
for ruptured AVMs (4.8%, 95% CI: 3.9–
5.9%) compared to unruptured (1.3%, 
95% CI: 1.0–1.7%) lesions at the initial 
presentation. The recently published 
findings from the ARUBA randomized 
controlled trial (discussed in section 
2.1.6.7) reported a 2.3% crude annual 
rupture rate for previously  unruptured 
and untreated AVMs.71 The risk factors 
found to be significant by the existing 
natural history literature mainly consist 
of patient characteristics and anatomical 
features of the lesion.68 The modifiable, 
classic cerebrovascular risk factors, 
such as smoking and hypertension, 
have not been directly associated with 
the risk of rupture in AVM patients, and 
are discussed more in detail in section 
2.3.2. The most often reported predictors 
for AVM hemorrhage during follow-
up include prior hemorrhage, larger 
diameter and deep or infratentorial 
location.66, 67, 72 Predictors for hemorrhage 
in the initial presentation have only been 
reported in a few studies, in which two 
have reported similar risk factors of 
deep or infratentorial location and small 
diameter,73, 74 however, opposite findings 
have been reported by one study.75 The 
annual mortality rates for AVM patients 
range from 0.7 to 2.9%, however, reports 
taking into account the background 
population mortality are scarce.13, 63, 
76-79 Hemorrhagic presentation was 
associated with increased mortality in the 
study by ApSimon et al., however, neither 
Ondra et al. nor Crawford et al. found 
any difference in the mortality between 
hemorrhagic and non-hemorrhagic 
presentation.13, 76, 77 In the ARUBA trial 
50.4-month follow-up, there were 6 
deaths total in the whole study cohort, 
with no statistically significant difference 
between the medical management and 
interventional therapy groups.71 
2.1.6 Management
2.1.6.1 Current conservative 
management
For some patients the risks related to 
interventional treatment exceed the risk 
of rupture. In practice, these are patients 
either with a difficult-to-treat lesion or 
those whose cumulative rupture risk 
is not high, usually owing to old age 
during diagnosis. Furthermore, some 
patients do not wish to be treated with 
interventional methods, despite clinical 
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meaningfulness. In these cases, the 
current medical treatment is based on 
the symptoms of the patient and careful 
follow-up. As discussed earlier, of the 
patients who are diagnosed with an 
epileptic seizure caused by AVM 60% 
develop epilepsy within the following 5 
years.55 Antiepileptic drugs (AED) used 
in seizure-control vary between patients 
depending on the adverse effects, patient 
characteristics and preferences. Chronic 
headaches are a common complaint with 
AVM patients and create a meaningful 
goal for conservative management.6 
ARUBA (discussed in section 2.1.6.7) did 
not find any difference in the outcomes 
for headache in their comparison of 
interventional therapy and medical 
management, although this was not a 
primary end-point in their study.53 There 
are no studies assessing the usefulness 
of medication in the treatment of AVM-
associated headache.80 In the more 
acute scenario after AVM rupture, the 
cardiorespiratory situation as well as other 
systemic responses need to be treated. 
These include treatment of systemic 
hypertension, fever, hyperglycemia and 
intracranial hypertension, and deep vein 
thrombosis prophylaxis.81 An important 
part of the conservative treatment is also 
the monitoring in the intensive care 
unit, which allows quick responses to 
the changes in a patient’s condition in 
acute scenarios. 
2.1.6.2 Introduction to 
interventional therapy
As in all interventional treatment 
modalities, there are several major 
treatment-related risks. These risks need 
to be carefully weighed against the risks 
of hemorrhage and its consequences. 
The panel of the European consensus 
conference on unruptured brain AVMs 
concluded that treatment complications 
may overcome the risk of hemorrhage, 
however, with young patients the risk 
of complications from treatment are 
far more minor than the risk of rupture 
with low-grade AVMs.70 In contrast, 
the panel regarded a life expectancy of 
minimum 20 years as a precondition 
for interventional treatment, meaning 
that patients with unruptured AVMs 
aged over 65 years should preferably 
be treated conservatively.70 Other 
factors that need to be considered 
when planning the treatment are first 
the clinical presentation of the patient 
(symptomalogy, cumulative rupture risk, 
patient’s opinion), second the anatomical 
features of the AVM, third the institutional 
preferences and policies, and finally the 
expertise and availability of the personnel 
performing the interventional modality 
of choice.82 Especially with lesions that 
have already ruptured, it is advisable 
to go into interventional management 
more eagerly, since previous rupture 
notably increases the risk for subsequent 
hemorrhage.83 
The goal of AVM treatment is a 
total occlusion of the lesion, as even the 
smallest residuals pose a significant risk of 
hemorrhage.52 Occasionally, treatment can 
be indicated to achieve control of epileptic 
seizures or to stop progressive neurological 
symptoms from developing.5 AVMs 
can be treated with microneurosurgery, 
endovascular embolization, stereotactic 
radiosurgery (SRS) or a combination of 
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these. Microsurgical resection is often 
regarded as the gold standard for Spetzler-
Martin grade (SMG)  I and II AVMs.54 SRS 
can also be used as a primary method 
for AVM occlusion or after endovascular 
embolization.84 Finally, embolization 
is most often used as an adjunct either 
before microsurgery or SRS, however, for 
carefully selected cases it can also serve as 
a primary treatment modality.84 Surgical 
resection is often more efficient than the 
endovascular methods, which might need 
multiple treatments before the lesion is 
completely eradicated.54, 85 However, 
microsurgery requires an open cranial 
surgery, which usually takes longer to 
recover compared to embolization.54 SRS 
can be needed in the treatment plans of 
the more complicated AVMs.86 A problem 
with SRS is possible ineffectiveness, as it 
might take up to three years to reach total 
obliteration.53 Furthermore, the desired 
treatment effect might not be reached 
at all, despite sacrificing the adjacent 
parenchyma to radiation edema or even 
necrosis.6 However, the risks related to SRS 
on eloquent or deep areas of the brain are 
considered minor to the risks associated 
with microsurgery, and therefore it is 
sometimes the preferred modality with 
small unruptured AVMs.70 Also, for large, 
inoperable AVMs, staged radiosurgery 
might be the method of choice if lesion 
eradication is deemed necessary.70
2.1.6.3 Microsurgical treatment 
AVM surgeries create one of the most 
difficult fields of neurosurgery, and 
therefore should be directed only to 
specialized institutions.87 What makes 
AVMs difficult to operate on is not only 
the nature and variety of the lesions, but 
also the rarity. Everything begins before 
the operation itself with careful planning 
and a review of the available images. 
From the angiographic images, the 
feeding arteries, the territories feeding 
the nidus, the transit arteries, the deep 
white matter feeders, the perforating 
arteries’ involvement, the diffuseness of 
the nidus, the intranidal and extranidal 
aneurysms and the nature of venous 
drainage are evaluated. From MRI and 
CT images, the size and relationship of 
the nidus to the adjacent parenchyma and 
the surface of the brain can be evaluated, 
as well as the type of a possible associated 
intracranial hemorrhage. The positioning 
of the patient during the surgery needs 
to be carefully planned in relation to the 
craniotomy, the approach into the lesion 
and the general principles related to, 
for example, hemodynamics. Modern 
operating microscopes are of the greatest 
importance.88 Otherwise, the operations 
can vary significantly between patients, 
and the following steps introduced here 
are only to provide a general picture of 
AVM surgeries. 
The operation itself begins with the 
appropriate craniotomy, after which the 
dura is inspected for adherents to the 
dura.88 After dural opening, the feeding 
arteries, the venous outflow and the 
transit arteries are located, with the help 
of indocyanine green videoangiography 
(ICG) if needed (Figure 9). The resection 
generally begins from the arterial side 
and progresses toward the venous side, 
therefore it is essential to distinguish the 
veins from the arteries before beginning 
occlusion.88 An intraoperative AVM 
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hemorrhage can result from a premature 
occlusion of the draining veins and this 
might lead to catastrophic consequences.88 
In particular, the main draining vein should 
be preserved and carefully handled.12 The 
coagulated vessels are then cut carefully 
while inspecting the possible signs of 
bleeding owing to inadequate coagulation. 
The small feeder arteries are the most 
difficult to coagulate, as the vessels do 
not have enough arterial wall for effective 
coagulation.12 Bleeding from these vessels 
can turn the surgery into a catastrophe if 
not controlled promptly. Small clips can 
be used to try control the bleeding, but 
the technique used more often in our 
clinic is the so-called dirty coagulation.88 
Basically, the idea is to coagulate a small 
portion of the surrounding gliotic tissue 
with the vessel. Temporary clipping may 
be especially useful if it is still uncertain 
whether some particular vessel is a true 
feeder, an en passage artery that needs to be 
preserved, or even an arterialized draining 
vein that should not be coagulated at too 
early a stage (Figures 10 and 11). The final 
step in the removal is the coagulation and 
cutting of the last draining vein, which 
should at this stage be dark owing to the 
lack of arterial blood flowing through the 
nidus from the arterial side. Again, ICG 
can be used in the evaluation of the possible 
remaining feeders, since in the case of 
no remaining feeders the remaining vein 
should only fill in a retrograde fashion. 
After the final coagulation and cut, the 
nidus can be removed and the remaining 
area is carefully inspected to detect the 
remaining vessels, which could cause a 
hemorrhage if not coagulated. Finally 
before the closure, the surface of the 
resection cavity is coated with fibrin glue 
and Surgicel.52 
In a literature review by Bradáč and 
Beneš comprising of 4296 patients in 32 
surgical series, the mean efficacy (complete 
obliteration of AVM) was 96.9% (95% CI: 
95.7–97.9%).12 In the same review, the 
mean complication rate was 7.1% (95% CI: 
5.6–8.8%), ranging from 1.2% to 21%. The 
complication rate increases as the anatomy 
becomes more complex.89-91 Eloquence, in 
particular, is regarded as a problematic 
anatomical feature.70 Therefore, it is 
sometimes advisable with eloquently 
located lesions to choose radiosurgery over 
microsurgery or endovascular treatment.70 
Figure 9. Intraoperative view of a cortical AVM, after craniotomy and dural opening (left). 
Intraoperative ICG videoangiography can be used to understand the flow of the AVM, to distinguish 
the feeding arteries from the arterialized veins (right).
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2.1.6.4 Stereotactic radiosurgery 
and therapy
In SRS, radiation is focused to AVM 
by using a variety of instruments 
and techniques over a single session. 
If multiple sessions are needed, for 
instance if the radiation dose needs to 
be fractioned because of proximity of a 
vital structure, the intervention is called 
stereotactic radiotherapy (SRT). SRS 
and SRT can be provided with different 
equipment and sources of radiation: the 
Gamma Knife©, linear accelerators and 
proton beam radiosurgery, and, despite 
the names, these methods are non-
surgical.6 The mechanism of action 
Figure 10. Arterial feeders on the perimeter of the nidus are sharply dissected free for coagulation 
or clipping.
Figure 11. Applying a temporary clip on an arterial feeder. Clips are usually removed at a later stage 
and the artery coagulated with bipolar cautery and then divided. 
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remains incompletely understood, 
however, according to current knowledge 
the radiation induces a destruction of 
the endothelium and a proliferation of 
myofibroblasts, which help occlude the 
lesion.92 Owing to these mechanisms, 
achieving a total occlusion usually 
takes 2–3 years, during which the risk 
of hemorrhage is still significant.93 SRS 
and SRT are regarded effective for AVMs 
smaller than 3.5cm in diameter.6 In a 
literature review of 9489 patients from 
45 studies, the mean efficacy of these 
methods were 64.2% (95% CI: 59.4–
68.9%), ranging from 35–92%.12 Factors 
associated with better obliteration 
rates include small AVM size, non-
eloquent location and low-flow pattern.94 
Understandably, radiation can induce 
adverse effects to the surrounding tissues, 
which increases the complication rates 
of this modality. These complications 
include blood–brain barrier breakdown, 
necrosis, edema and cyst formation.92 
Roughly 10% of patients get symptomatic 
adverse changes, however, the risk 
is associated with the location of the 
AVM, target volume and margin dose 
(surrounding normal tissue dose).84 
These adverse effects can be treated 
to some extent with corticosteroids, 
and in some cases with bevacizumab.95 
However, 2–3% of patients experience 
permanent neurological changes from 
adverse effects.96 
2.1.6.5 Endovascular treatment
In endovascular embolization the 
feeder arteries and the draining veins 
are occluded using liquid endovascular 
agents, such as n-butyl-2-cyanoacrylates, 
or more frequently Onyx®, which 
is ethylene vinyl alcohol copolymer 
dissolved in a potent organic solvent 
dimethyl sulfoxide. These are guided into 
the AVM using guiding catheters and 
microcatheters. Onyx is not a glue like the 
cyanoacrylates, therefore it does not have 
the same problems of adherence of the 
microcathethers.97 In addition to liquid 
embolisates, platinum flow coils can be 
used in occlusion.12 The standard method 
is to access the AVM transarterially, 
however, transvenous methods also exist 
as an option. In addition to the liquid 
embolisates, detachable coils can also be 
used to occlude large arterial feeders.84 
Embolization is most often used as 
an adjunct to microsurgery or SRS to 
occlude or reduce the feeders of a large 
AVM, however, there are considerable 
differences in institutional preferences.12, 
45 Preoperative embolization is covered 
in section 2.1.6.7 about multimodal 
therapies. 
As with all the interventional methods, 
embolization possesses its own risks of 
complications, most notably hemorrhagic 
complications either intracranially or 
during the navigation.98, 99 In a literature 
review by Bradáč and Beneš comprising 
4787 endovascularly treated AVM patients 
from 33 series (larger than 30 patients) the 
mean efficacy was 29.6% (95% CI: 22.6–
37.2%), meaning that 29.6% of patients 
treated with Onyx received total occlusion 
of the lesion.12 However, for highly selected 
patient series of simple-featured AVMs, 
the obliteration rate can be as high as 
96%.100 Regarding complications, the same 
review concluded that the more aggressive 
the attempt to completely occlude the 
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lesion, the larger the complication rate, 
with the mean of 7.4% (95% CI: 6.3–
8.5%), ranging from 2% to 17%.12 The 
most common complications are ICH 
and ischemic stroke (IS).101 Recurrent 
AVMs, verified with DSA, have been 
reported even after a total obliteration with 
embolization.102-105 In a literature review by 
Potts et al. consisting of 32 studies with 
3624 patients, however, of the 668 patients 
with a reported total obliteration, only 4.5% 
had a reported recurrent AVM in a follow-
up angiography.106 Based on their results, 
they concluded that embolization can 
provide a permanent cure, but follow-up 
angiographies are still justified. Reasonable 
explanations for the recurrence include 
recanalization through the embolized 
vessel, revascularization, and as a biasing 
factor an incomplete embolization in the 
initial phase, owing to poor visualization 
to all the compartments of the nidus.107 
Notably, curative embolization often 
requires multiple treatments, and often 
a total obliteration cannot be met despite 
efforts.104, 108 In rare cases, embolization can 
be used in a palliative manner to reduce 
symptoms owing to the vascular steal 
phenomenon caused by the AVM or to 
treat AVM-related high-risk lesions, such 
as associated aneurysms or arteriovenous 
fistulae.84
2.1.6.6 Multimodal strategies
Embolization (introduced above) can 
be used before microsurgery to aid 
in the resection. Deep feeders, which 
are generally considered problematic 
for microsurgical resection, can be 
selectively embolized before operation, 
although this approach poses its 
own treatment-related risks.70 There 
is no consensus about the timing of 
embolization in relation to surgery, as no 
evidence supporting either an immediate 
or delayed presurgical approach exists.84 
However, our institutional preference 
favors surgery the same or next day to 
avoid embolization-induced ruptures. 
Targeted embolization can also be used 
presurgically to occlude AVM-related 
aneurysms or a venous ectasia.12 Before 
Figure 12. DSA illustrating contrast agent filling the AVM before embolization (left). The AVM is 
embolized with Onyx, which is visible in a traditional X-ray image (middle). Postembolization 
DSA shows complete lesion occlusion, the radiocontrasting agent is similarly subtracted as the 
surrounding skull (right).
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SRS, embolization is commonly used 
with AVMs larger than 3cm in diameter.84 
The goal of this strategy is to reduce the 
size of AVM to optimize the effectiveness 
of SRS. Also, certain high-risk features 
can be treated endovascularly to reduce 
the rupture risk during the latency period 
of SRS.109 This is a rather new method, 
and there is not enough research evidence 
to support it yet.84 In addition, if the total 
obliteration of a large AVM cannot be 
met with staged SRS, it can be followed 
by surgery or endovascular treatment.70
2.1.6.7 ARUBA
ARUBA, a randomized controlled trial 
of unruptured brain arteriovenous 
malformations, has sparked a lot of debate 
about the treatment recommendations 
of AVMs.53 The trial was designed 
to compare interventional therapy 
(microsurgery, SRS, embolization) 
to medical therapy (i.e., conservative 
treatment for unruptured AVMs). The 
original trial was published in the Lancet 
with 226 patients with a 33-month follow-
up with the conclusion that the risk ratio 
for the primary end-point (death or a 
symptomatic AVM hemorrhage) in the 
medical-arm was 0.27 (95% CI: 0.14–
0.54) compared to the interventional 
arm.53 Recently, the ARUBA investigators 
published their long-term outcomes, 
namely after a mean 50.4 months 
(standard deviation (SD) =22.9 months) 
of follow-up, with similar conclusions 
that medical management should be 
preferred over interventional treatment 
in patients with unruptured brain AVM.71 
Owing to some issues  in the trial design 
and protocol, many have considered 
its results as not generalizable to all 
unruptured AVMs or to all interventional 
modalities.70 Altogether 1740 AVM 
patients were screened for the trial, 
however, 87% had to be excluded from 
the final cohort owing to various reasons: 
323 patients did not want to participate, 
in 177 cases the clinicians did not follow 
the study protocol and 1014 patients 
were excluded because they had had a 
previous intervention or hemorrhage 
from the AVM.53 Additionally, despite 
the interventional treatment arm having 
more than two-thirds of the patients with 
SMG I and II AVMs, only 5 patients in 
the arm were treated with microsurgery 
as monotherapy, compared to 80% of the 
patients with SRS and/or embolization. 
This proves especially problematic, as 
microsurgery is regarded as the golden 
standard for unruptured SMG I and II 
AVMs.110 Even with the extended follow-
up time, the occlusion rate of AVMs in 
the interventional group was a mere 
44%, illustrating these rather suboptimal 
treatment strategies in the interventional 
arm.71 This shortcoming in the outcome 
is reflected in the high event rate in the 
therapeutic group, which was almost 
50% higher than what was expected 
in their statistical power analysis and 
when compared to existing literature.110 
What re-occurred in their most recent 
publication was that the outcome rates 
in the interventional group were noted to 
be comparable to a meta-analysis by van 
Beijnum et al.6 For reference, this meta-
analysis reports death/symptomatic 
stroke rates of 7.4% (range 0–40%) after 
microsurgery, 6.6% (range 0–28%) after 
embolization and 5.1% (range 0–21%) 
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after SRS for unruptured lesions, whereas 
the comparable figures in ARUBA were 
29% (1.5–54%), 25% (7.6–55%) and 13% 




The SMG was introduced by Drs. Spetzler 
and Martin in 1986.111 In the grading 
system, patients are classified from 1 to 
5 depending on the anatomical features 
of their AVM.111 SMG is a surgical scale 
assisting in the decision-making of the 
treatment modality.87 It is commonly 
used in neurosurgical research.87 Table 
2 introduces the criteria used in SMG 
classification. Lesions are graded based 
on three categories: size of the nidus 
(1–3 points), eloquence (0–1 point) and 
venous drainage (0–1 point), leading to 
a minimum of 1 point and maximum 




The original SMG was converted to 
the 3-tier Spetzler-Ponce (SPC) in 2011, 
owing to similarities in the far-ends of the 
spectrum of the SMG (Table 2).87 From 
the studies using functional outcome 
instruments, such as modified Rankin 
Scale (mRS), it has been determined 
that the SPC A lesions are most often 
suitable for surgical management.5, 50, 112 
SPC B lesions create the trickiest group 
with regard to decision-making, falling 
between the SPC A lesions and the 
Table 2. Spetzler–Martin grade (SMG) deduction and translation into Spetzler-Ponce grade (SPC). 
*Eloquent location determined as brainstem, thalamus, hypothalamus, cerebellar peduncles, or 
sensorimotor, language or primary visual cortex.
Points for SMG, one set of points from each 
category: Size of the nidus; Eloquence; 
Venous drainage. 
Points Points from all three categories summed




1–3 pointsMedium 2 SMG 2
2 points altogetherLarge 3
Eloquence* SMG 3
3 points altogether SPC BNon-eloquent 0
0–1 point





0–1 point SMG 55 points altogetherDeep 1
Total 1-5
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difficult SPC C lesions. One part of this 
trickiness is the phenomenon that to fall 
into the SPC B category (=SMG 3) you 
can have many various combinations of 
the anatomical variables. This leads to 
this group being rather heterogenous 
compared to the SPC A and SPC C 
groups.113 The treatment of SPC B 
patients has created a lot of debate on 
the microsurgical field. To this question 
we aimed to provide new insight with our 
long-term HRQoL data on AVM patients.
2.1.7.3 Lawton–Young 
grading scheme
A supplementary grade was developed 
to be used in addition to the SMG, to 
improve the accuracy of the evaluation 
of treatment outcome in patients with 
brain AVM.114 The grade takes into 
account a patient’s age, the hemorrhagic 
presentation and the nidus compactness 
(Table 3). It has been validated with 
multicenter studies and has shown better 
accuracy in predictions than SMG alone, 
especially with cerebellar AVMs.115-117 
Table 3. The Lawton–Young grading system. 
Patients can receive up to 5 additional points 
which illustrate the difficulty of surgery.
Age
<20 years 1 point
20-40 years 2 points







2.2 Outcomes of patients 
with brain arteriovenous 
malformation
In a systematic review and meta-analysis 
of AVM treatment comprising 142 study 
cohorts and 13,698 patients with 46,314 
patient-years of follow-up, van Beijnum 
et al. compared the outcomes after each 
treatment modality.6 Overall, male sex, 
younger age, SMG I–III AVM, small AVM 
size and exclusively deep venous drainage 
were associated with a lower case fatality. 
Table 4 compares the findings for each 
modality (as a primary modality only). 
SRS had the lowest case fatality; however, 
the hemorrhage rates were high after 
SRS and embolization. Microsurgery 
had low hemorrhage rates in follow-up 
and a high proportion of patients who 
received a total obliteration of the AVM.6 
These patient cohorts represent selected 
AVM patients, since they are collected 
from observational studies. To date, 
there is no randomized controlled trial 
(RCT) comparing interventional AVM 
treatment modalities against each other.
2.2.1 Surgically treated patients
For the low-grade AVMs (SPC A), surgery 
is often regarded as the gold standard. 
In a summary of 12 studies consisting 
of 1235 surgically treated patients with 
unruptured low-grade AVM, the mean 
postoperative morbidity was 2.2% 
(range 0–6.6%), and mortality 0.3% (0–
2.2%).118 After ICH, the mortality rate 
for ruptured AVMs is understandably 
higher, numbers as high as 67% have 
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been reported,60 however, these figures 
arise mostly from the historical patient 
series. With modern medical technology, 
the numbers from high-volume centers 
are around 12% to 20%.3, 51 In Table 5, the 
surgical patient series published in the 
2010s reporting the functional outcomes 
measured with mRS are collected. The 
factors associated with a better functional 
outcome postoperatively are younger 
age,118 unruptured presentation,50, 118 small 
AVM size,50, 119 non-eloquent location,119 
cortical venous drainage,119 SPC A lesion 
type,50, 119 and good preoperative mRS.118
However, compared to the other causes 
of ICH, AVM patients have a lower odds 
of death (odds ratio (OR) =0.5, 95% CI: 
0.4–0.7) and a better odds of favorable 
discharge from the hospital (OR=2.0, 95% 
CI: 1.4–3.0).51 The better outcomes among 
ICH patients have been hypothesized to 
result from the AVM possibly bleeding 
into the nidus itself, or to the venous side 
and therefore sparing the healthy brain 
surrounding the lesion. Eloquent location 
is one of the factors associated with a worse 
outcome after a microsurgical obliteration 
of AVM. In particular, a sensorimotor or a 
language eloquence have been associated 
with poor outcomes.123 
2.2.2 SRS and SRT patient series
SRS and SRT are typically chosen as the 
treatment modalities for patients whose 
AVM seems too risky for microsurgical 
resection.70 These risky features include 
deep or eloquent location of lesion, 
large size and various patient-related 
factors (e.g., if the induction of general 
anesthesia is too risky). These differences 
in the background characteristics of the 
patients understandably are related 
to the outcomes of SRS, compared to 
patients treated with other modalities.84, 
96 Predictive factors for a successful 
outcome (complete obliteration of the 
lesion after the latency period) are AVM 
size (OR=0.88, 95% CI: 0.81–0.96), non-
eloquent location (OR=3.2, 95% CI: 1.29–
7.93), absence of perinidal angiogenesis 
(OR=2.61, 95% CI: 1.21–5.64) and low-
flow pattern (OR=3.47, 95% CI: 1.6–
7.53).94 Several different SRS and SRT 
outcome scales have been developed 
to assess outcomes with regard to both 
obliteration and the functional outcome 
of the patient, and partly owing to 
this there is a shortage of pure mRS 
outcome studies reported among SRS 
patients.124 However, these radiosurgical 
scores have shown associations to 
Table 4. van Beijnum J, van der Worp HB, Buis DR, et al. Treatment of Brain Arteriovenous 
Malformations: A Systematic Review and Meta-analysis. JAMA. 2011;306(18):2011–2019. doi:10.1001/
jama.2011.1632
Case-fatality* Hemorrhage rate* Complications‡ Obliterationº
Microsurgery 0.68 (0.61-0.76) 0.18 (0.10-0.30) 7.4% (0-40%) 96% (0-100%)
SRS 0.50 (0.43-0.58) 1.7 (1.5-1.8) 5.1% (0-21%) 38% (0-75%)
Embolization 0.96 (0.67-1.4) 1.7 (1.3-2.3) 6.6% (0-18%) 13% (0-94%)
Overall 0.68 (0.61-0.76) 1.4 (1.3-1.5) - -
*per 100 person-years (95% CI), ‡ leading to permanent neurological deficits or death, median 
(range), º median (range)
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mRS scores, although they are not 
completely interchangeable.125 In a 
massive multi-center study of 2236 
AVM patients (mean age 36.0 years, 
SD=±16.5y) undergoing Gamma Knife 
SRS with a mean 7 years of follow-up 
and average obliteration rate of 64.7%, 
the combined radiosurgical outcome was 
favorable (obliteration without post-SRS 
hemorrhage or permanent SRS-related 
symptoms) in 60.3% of the patients.126 
Predictors for poor outcome were high 
nidal volume, prior AVM hemorrhage, 
prior embolization, eloquent location, 
high number of isocenters and lower 
margin dose. In their analysis, there were 
radiation-induced imaging changes, 
which were symptomatic, in 9.4% of the 
patients, and the risk for developing these 
was increased in patients who received a 
margin dose greater than 24Gy.126
2.2.3 Endovascular patient series
The introduction of Onyx has improved 
the endovascular outcomes. Still, only 
a few patient-series with patients with 
fully occluded lesions exist, illustrating 
the rather adjunctive role of embolization 
in the modern treatment AVMs aiming 
for ‘’curative’’ treatment.54, 113 This is 
strengthened by the finding that a higher 
complication rate from treatment is 
associated with the aggressiveness of 
the endovascular treatment.127 Hence, 
pre-surgical embolization not aiming 
for a curative treatment can be lower 
in the complication rates compared 
to embolization aiming for a total 
lesion occlusion.128 This periprocedural 
complication rate is in relation to the 
anatomic characteristics of the lesion, 
since SMG V lesions might harbor a 
25% complication rate, whereas for SMG 
II lesions the number can be five times 
Table 5. Microsurgical series of patients with brain AVM. Favorable mRS dichotomized classes are 
reported in the mRS column, followed with the percentage of patients with favorable mRS at follow-
up, and number of patients in the whole study population. 
Authors Follow-up 
time, mean






Potts et al.118 1.8 years SPC A unruptured 0-1 91 112
1.6 years SPC A ruptured 0-1 70 120
Javadpour et al85 6 months 71% SPC A unruptured 0-1 94 45
Schramm et al50 5.3 years 40% SMG II,30% SMG III, 50% ruptured 0-1 89.6 288
Morgan et al119 1.0 years SPC A 0-1 98.1 359
1.0 years SPC B 0-1 77.8 203
Tong et al120 6.4 years Cerebellar AVMs, 95% ruptured 0-2 89.5 181
Pohjola et al121 9.7 years Ruptured infratentorial AVMs 0-2 66.6 36
Madhugiri et al122 4.0 years Brainstem AVMs, 92% ruptured 0-2 51 39
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lower.129 Other factors associated with an 
impaired functional outcome (mRS>0) 
include the presence of intranidal 
aneurysms, increasing age, and a deep 
venous drainage.108, 127 There are very few 
purely endovascular outcome studies 
of AVM patients, mostly because of 
the treatment policies, which usually 
include other modalities owing to the 
inefficiency of embolization to totally 
occlude AVMs. However, embolization 
can yield favorable results if the patients 
are carefully selected, preferably in a 
multidisciplinary meeting.70 However, 
the results from the few studies including 
patients treated with embolization only 
illustrate that the results are not as 
favorable as in the analogous surgical 
series: a study  by Iosif et al. with a 
patient-series from their high-volume 
endovascular center, which included 
73 patients with fully occluded SMG I–
II lesions, the outcomes at 6 months 
follow-up were mRS 0 for 42.4%, mRS 
1 for 21.9% and mRS 2 for 26.0% of the 
patients.130  Owing to their decision of a 
dichotomization cut-point (mRS 0–2 = 
favorable), they reported that 90.5% of 
the patients received a favorable outcome 
and concluded that endovascular 
methods offer good clinical outcomes.130 
The lack of a purely endovascular series 
was recently discussed in a meta-
analysis in which, out of the 1605 
endovascular articles published, only 15 
met the inclusion criteria for a purely 
endovascular series.99 These 15 studies 
comprised of 597 patients with intent-
to-cure embolization. The treatment 
goal (total obliteration) was achieved in 
58.3% of the patients with an overall 
complication rate of 24.1%. The lesions 
were SMG I–III in 70.9% of the cases, 
with 34% of SMG III AVMs.99 
2.2.4 Multimodal treatment 
patient series 
In a recent retrospective analysis of 
258 SPC A patients (48% presented 
with hemorrhage) treated with pre-
operative embolization, the authors 
reported mRS <2 outcomes for 92.5% of 
the patients with unruptured AVM, and 
88.0% for those with ruptured AVMs 
after a mean of 4.5 years follow-up.131 
Irreversible neurological morbidity 
in this study occurred in 1.2% of 
the patients.131  An older study by 
Hartmann et al. with 119 patients with 
mostly medium- or high-grade lesions 
treated with endovascular embolization 
followed with microsurgical extirpation 
concluded that an increased treatment 
risk was associated with the combined 
therapy of endovascular therapy and 
microneurosurgery in the previously 
unruptured AVMs of their series.132 Of 
these 35% of patients who presented 
with hemorrhage, 8% had SMG I, 27% 
SMG II, 40% SMG III and 22% SMG 
IV lesions. The factors associated with 
worsened long-term outcome were a 
deep venous drainage (OR 3.24, 95% 
CI: 1.35–7.80), an eloquent location 
(OR 2.42, 95% CI: 1.02–5.73), initial 
presentation with hemorrhage (OR 0.27, 
95% CI: 0.11–0.69) and the maximum 
AVM diameter (OR 1.05, 95% CI: 1.01–
1.09, per millimeter increase in size).132 
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2.2.5 HRQoL outcomes
Before our HRQoL study,I only a few 
papers on the QoL of AVM patients 
had been published.56, 133-136 These had 
either been targeted at patients treated 
with radiosurgery pediatric patients, or 
had been rather small in sample size. 
The first one of these, published in 
2002, discussed the impact of Gamma 
knife treatment before the total AVM 
obliteration on the QoL of 39 adult 
AVM patients.135 Their conclusion was 
that the experience of hemorrhage did 
not significantly affect the perceived 
QoL, probably owing to the ‘’fear of 
the unknown’’ in the non-hemorrhagic 
group, whose QoL was decreased.135 
Another RT QoL series published in 2012 
with 78 AVM patients who had presented 
with seizure concluded that seizure 
freedom was significantly associated 
with an improved QoL and attaining 
employment after mean 7.6 years follow-
up.133 The largest impairments in QoL 
were perceived in the emotional domain 
(‘’Do you feel happy about your life?’’) 
and the lowest in the familial domain 
(‘’Are you satisfied with your role as a 
family member or your family member’s 
support?’’).133 In 2016, the first and so far 
only paper about QoL in pediatric AVM 
patients reported that in 26 patients with 
the mean age at diagnosis of 12.5 years 
and 6.8 year average follow-up period, 
factors associated with an improved 
QoL were a special education, corrective 
devices and functional status.134 In 2017, 
the first microsurgical series on adult 
AVM patients’ HRQoL was published.56 
Their study was limited by the small 
number of only 25 microsurgically treated 
patients. They discovered that the QoL 
of AVM patients was not significantly 
different from the age-matched values 
from the general population, and that 
patients with the main symptom of 
headache at diagnosis had impaired 
HRQoL compared to other causes.56 
Finally, in 2018, another QoL study with 
adult AVM patients was published, with 
the main intention to compare surgery to 
conservative management of unruptured 
AVMs.136 The study included patient 
cohorts from Scotland and Australia, 
which were independently analyzed. 
Neither study population showed a 
significant difference in the HRQoL 
at 12 months between surgically or 
conservatively treated patients.136 
2.3 Cerebrovascular 
risk factors
The discovery of high diastolic blood 
pressure as an IS risk factor dates back 
to 1967 and it sparked research into other 
cerebrovascular stroke risk factors.137 
Nowadays, it is estimated that as much 
as 90% of ISes or primary intracerebral 
hemorrhages (PICH) can be explained by 
the modifiable risk factors of high blood 
pressure, smoking, obesity, physical 
inactivity, poor diet, diabetes, extensive 
alcohol consumption, heart diseases, 
dyslipidemias and mental distress.138-140 
Cigarette smoking is regarded as one 
of the strongest etiological risk factors 
for stroke.139, 142-145 Independently, it can 
more than double the risk of stroke.146, 
147 These findings have naturally 
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sparked the etiological studies of 
other types of hemorrhagic strokes, 
and smoking has been established as 
having a key role in the risk profile 
of these diseases as well.148-151 A recent 
case–control study with Finnish twins 
was able to strongly connect cigarette 
smoking to fatal SAH, sealing its role 
as the most dangerous environmental 
risk factor of SAH patients.152, 153 In 
their study, they also found a trend 
toward the other commonly reported 
risk factors, however, these findings 
were nonsignificant. Additionally, they 
reported that alcohol consumption was 
independently associated with fatal 
SAH, however, not after adjusting for 
smoking,152 delineating the connection 
between notorious lifestyle habits. In the 
following section I review the known risk 
factors in non-traumatic hemorrhagic 
stroke. 
2.3.1 SAH risk factors
Non-traumatic SAHs are caused by 
ruptured intracranial aneurysms (IA) in 
roughly 80% of the cases.154 The lesions 
are roughly ten times more prevalent 
than AVMs, however, most IAs remain 
unruptured and unnoticed for the whole 
lifetime.155 IA patients are on average 10–
20 years older during diagnosis compared 
to AVM patients, and there is a female 
predominance.156, 157 Similarly, as in AVMs, 
most IAs present with hemorrhage.154 
This complicates the determination 
of risk factors, as we cannot ascertain 
the point of time when the patient has 
developed the lesion. Therefore, risk 
factor analyses of etiology and rupture 
have some understandable overlapping. 
When looking at SAH, the most well-
recognized risk factors are smoking 
and hypertension (Table 6). These have 
Table 6. Population-based case–control studies of males and females about the risk factors for SAH. 
Modifiable risk factors found significant by the study. 
No of SAH Population SM HT AL OC TC DM BMI
Anderson151 432 ANZ X X X X
Bonita163 115 New Zealand X X
Fogelholm149 114 Finland X
Hannaford164 73 UK X
Isaksen165 26 Norway X
Kissela166 107 USA X X X X
Lindbohm153 543 Finland
Longstreth167 149 USA X X
Müller160 117 Norway X X
Rautalin152 120 Finland X
Sandvei168 132 Norway X X
Sundström169 2659 Sweden X X X
SM = smoking, HT = hypertension, AL = alcohol, OC = oral contraceptives, HRT = hormonal 
replacement therapy, TC = high total cholesterol, DM = diabetes, BMI = body mass index, ANZ = 
Australia and New Zealand
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also been recognized as risk factors for 
IA formation.158, 159 Other unmodifiable 
risk factors for both the formation and 
rupture include female sex, age, family 
history of IAs, ethnicity, and autosomal 
polycystic kidney disease.160-162 
2.3.2 Smoking as a cerebrovascular 
risk factor
Smoking not only increases the risk 
of IS and PICH, it is associated with 
many other cerebrovascular diseases, 
as discussed. Cigarette smoke contains 
substances which affect the immune 
and inflammatory response in the 
brain vasculature. This happens via 
promoting angiogenesis by upregulating 
growth factors, such as VEGF, and 
sustaining a chronic inflammatory 
state and hypoxia.170, 171 As mentioned 
in earlier sections of this book, brain 
angiogenesis is predominantly driven 
and mediated by VEGF.36 VEGF gene 
transcription is upregulated by various 
factors, such as hyperglycemia, pro-
inflammatory cytokines, and hypoxia.170, 
172 Upregulation leads to endothelial cell 
proliferation, migration and increase 
in capillary permeability.40 Nicotine 
in cigarette smoke is one of the most 
studied and distinguished risk factors for 
IA formation, growth and rupture.173-176 
Additionally, among the 4000 other 
ingredients in tobacco smoke, reactive 
oxygen species have been associated with 
vascular endothelial dysfunction.177, 178 
Nicotine has, in mouse IA models, caused 
upregulation of mRNA levels of VEGF, 
PDGF-β and inflammatory cytokines 
such as interleukin-1, interleukin-6, 
tumor necrosis factor-α and matrix 
metalloproteinases (MMP) in cerebral 
arteries.172, 179 Downstream from VEGF 
lies the Ras signaling pathway, ultimately 
leading to endothelial cell proliferation, 
migration and the formation of three-
dimensional structures in angiogenesis.36 
VEGF also plays an important role in 
blood–brain barrier dysfunction, and can 
strongly increase vascular permeability 
(50,000-fold stronger than histamine).180 
The endothelium dysfunction sets off 
a cascade of inflammatory responses: 
the recruitment of leukocytes and the 
increased secretion of immunoglobulins, 
complement and other inflammatory 
and immunologic components.181 
2.3.3 Modifiable AVM risk factors  
The first reported evidence of modifiable 
risk factors behind AVMs was published 
in 1998 and it suggested an association 
between hemorrhagic AVM presentation 
and hypertension.182 Probably the largest 
limitation of this report was the relatively 
small sample size, as the analysis of 
hypertension included only 16 patients. 
The results of this study have not been 
replicated since. However, it opened up 
the conversation about the modifiable 
risk factors behind AVMs. Another risk 
factor familiar from other cerebrovascular 
diseases, smoking, has also been a target 
of some AVM investigators. However, 
before the publication of our study,II the 
only connection that had been found 
between AVM patients and smoking 
was with poor outcome after AVM 
intervention. The researchers behind 
these reports have hypothesized that 
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smoking reduces the likelihood of AVM 
obliteration when using microsurgery 
or SRS.183-185 The study mentioned 
in the beginning of this section 
assessed the connection between AVM 
hemorrhage and smoking, but did not 
find association.182 Lifestyle-related risk 
factors can be difficult to capture because 
data in patient registries often focus on 
the clinical aspects. With the rarity of 
AVMs, this combination of few patients 
and suboptimal data could explain why 
the connection between smoking and 
AVM patients had not been found before 
the publication of our study.II 
2.4 Outcome research
2.4.1 Introduction
Probably the most cited and appreciated 
definition of health was provided by the 
World Health Organization (WHO) in 
1948: ‘’Health is a state of complete 
physical, mental and social well-being 
and not merely the absence of disease or 
infirmity.’’186 Measuring health has always 
been at the core of medical research.187 
Outcome measures range from the 
traditional, morbidity- and mortality-
focused single-item instruments, to the 
modern, HRQoL-based health profiles 
and index scores. Modern medical 
research is increasingly turning toward 
the patient-reported outcome measures, 
whereas in the past it was mostly the 
clinician who evaluated the outcome at 
a specified end-point.188, 189 Nowadays, 
we can decide from numerous different 
scales which is the most suitable for 
our specific research interest. The more 
commonly used the scale, the more 
information we have about its behavior in 
certain scenarios or in statistical handling. 
The disease-specific tools can be handy 
in narrow research questions, but can 
lack sufficient validation regarding rare 
diseases. Despite being regarded as 
historical, the single-item outcome 
instruments measuring physical abilities 
still have their stronghold in medical 
research, as objective measures with little 
confounding factors.190 
2.4.2 Statistical features of 
outcome measurement
To evaluate the appropriateness of an 
outcome instrument, a certain pattern 
of statistical characteristics needs to be 
discussed. When testing the instrument 
in different scenarios, if we are able to 
recreate the results upon repeated testing, 
we can call the test instrument reliable (if 
no change is anticipated). Similarly, if the 
test is able to differentiate groups based 
on their results, when this is expected, 
the instrument is regarded reliable.191 
This feature, sometimes called test–
retest repeatability, can be statistically 
measured with uncertainty analyses.192 
Additionally, another essential feature of 
reliability is the unchangeability across 
different interviewers or assessors.191 
Validity measures the level at which the 
instrument estimates the desired features 
to be measured. Validation is a process, 
and therefore validation improves as the 
instrument is tested in different scenarios 
by different investigators. In this context, 
content validity and construct validity can 
be separated from each other; content 
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validity describes how well the instrument 
measures what it is intended to evaluate, 
and construct validity describes how 
precisely a nonphysical attribute can be 
measured by constructing this variable 
from multiple different sources (for 
instance, depression, which itself is 
a sum of certain psychiatric factors). 
Construct validity, per se, subsumes 
all other types of validity.193 The 
sensitivity of a test can be considered 
as a sum of discriminatory power and 
responsiveness. Discriminatory power 
is the magnitude at which a test can 
separate results from each other regarding 
different individuals or patient groups, 
again when difference actually exists. 
Responsiveness describes how well the 
test is able to distinguish changes in test 
results over time, again if there actually 
are changes in the results of individuals 
or groups.191
2.4.3 Health-related quality of life
Before discussing HRQoL in more 
detail, it is essential to distinguish the 
difference between HRQoL and QoL, 
which are often used interchangeably.194 
QoL aims to measure not only 
health-related issues like mobility, 
symptomalogy, mental well-being, but 
also social and economic well-being. 
In this sense, it is much harder to 
translate into index figures or QoL 
profiles. Despite being a narrower scale, 
the HRQoL instruments can cover a 
significant amount of a person’s life and 
are brilliant indicators of health benefits 
or the effects of morbidity.194 Regarding 
HRQoL, there are various different 
outcome assessment methods: generic, 
preference-based and disease-specific 
instruments.195 The generic instruments 
are the most commonly used and can 
be applied to different morbidities 
regardless of the study cohort.196 This also 
allows the inter-morbid comparison of 
HRQoL. Preference-based instruments 
summarize the components of HRQoL 
into a single index score, usually from 
0 to 1, and can therefore be easily 
applied to cost-effectiveness analyses.195 
The transformation into a single index 
(or sometimes called utility) score 
is created using an algorithm with 
weighted values for each dimension 
of the HRQoL domains, usually 
derived from the general population 
by random sampling. Disease-specific 
instruments are used and designed 
for the patient groups harboring a 
specific illness, and are not therefore 
as easily adjustable to the general 
population as the generic instruments, 
nor do they allow for the comparison 
between different illnesses.188 Most 
of the modern instruments are both 
generic and preference-based, and 
by combining both of these features 
investigators are allowed to compare 
a specific patient population to the 
general population, using both the index 
scores and the HRQoL profiles.194  The 
HRQoL instruments measure not only 
the physical, but also the social and 
mental domains of health, which play 
a major role in the financial burden of 
the morbidity.197, 198 Notable, however, 
is that the more complicated real-life 
variables we aim to measure, the more 
we need to deal with uncertainties and 
bias.188 There is inevitably, to some 
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research began developing in the 1950s.187, 188 For many years, the definitive outcome for 
treatment had been reported narrowly, with variables illustrating either morbidity or 
mortality.199 Before the 1960s, morbidity assessment was often based on either the 
functional ability or the activities of daily living, both reported with a single-item score, but in 
the 1960s, medical literature began discussing QoL.188, 200  From 1970 to 1981, more than 
twelve generic HRQoL measures were published.201 Each of these included multiple health 
profiles, mainly descriptive and constructed to be used in health services research.201 
However, it was not until the Medical Outcomes Study SF-20 Health Survey in 1988 that the 
first short-form questionnaires were first introduced.202 After this, there has been a rapid 
proliferation of HRQoL instruments. In 2020, the five most-used generic preference-based 
instruments were the EQ-5D, SF-6D (which can be calculated from SF-12), HUI, 15D and 
AQoL.203, 204 Figure 14 illustrates the timeline of the development of HRQoL instruments. 
 
Figure 14. Timeline of the development of HRQoL instruments 
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values for each dimension of the HRQoL domains, usually derived from the general population by 
random sampling. Disease-specific instruments are used and designed for the patient groups 
harboring a specific illness, and are not therefore as easily adjustable to the general population as 
the generic instruments, nor do they allow for the comparison between different illnesses.188 Most 
of the modern instruments are both generic and preference-based, and by combining both of these 
features investigators are allowed to compare a specific patient population to the general population, 
using both the index scores and the HRQoL profiles.194  The HRQoL instruments measure not only the 
physical, but also the social and mental domains of health, which play a major role in the financial 
burden of the morbidity.197, 198 Notable, however, is that the more complicated real-life variables we 
aim to measure, the more we need to deal with uncertainties and bias.188 There is inevitably, to some 
extent, environmental and individual characteristics such as religion or culture affecting one’s health 
views, which can complicate generalizability of results across nationalities and cultures (Figure 13).195 
 
Figure 13. Illustration of the aspects underlying reported health-related quality of life. Adapted from 
Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model 
f patient outcomes. JAMA. 1995;273:59-65. 
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extent, environmental and individual 
characteristics such as religion or 
culture affecting one’s health views, 
which can complicate generalizability of 
results across nationalities and cultures 
(Figure 13).195
2.4.3.1 History 
The demand for better outcome 
instruments has existed ever since 
qualitative medical research began 
developing in the 1950s.187, 188 For many 
years, the definitive outcome for treatment 
had been reported narrowly, with 
variables illustrating either morbidity or 
mortality.199 Before the 1960s, morbidity 
assessment was often based on either the 
functional ability or the activities of daily 
living, both reported with a single-item 
score, but in the 1960s, medical literature 
began discussing QoL.188, 200  From 1970 to 
1981, more than twelve generic HRQoL 
measures were published.201 Each of these 
included multiple health profiles, mainly 
descriptive and constructed to be used 
in health services research.201 However, 
it was not until the Medical Outcomes 
Study SF-20 Health Survey in 1988 that 
the first short-form questionnaires were 
first introduced.202 After this, there has 
been a rapid proliferation of HRQoL 
instruments. In 2020, the five most-used 
generic preference-based instruments 
were the EQ-5D, SF-6D (which can be 
calculated from SF-12), HUI, 15D and 
AQoL.203, 204 Figure 14 illustrates the 
timeline of the development of HRQoL 
instruments.
2.4.3.2 15D health-related quality 
of life instrument
The 15D HRQoL instrument is a 
generic, self-administered instrument 
for assessing HRQoL in adults.205 It can 
be used both as a profile and as a single 
index score measure. The questionnaire 
includes 15 dimensions: mobility, vision, 
hearing, breathing, sleeping, eating, 
speech, excretion, usual activities, 
mental functioning, discomfort and 
symptoms, depression, distress, vitality, 
and sexual activity. For each dimension, 
the respondent chooses one of the five 
ordinal levels best describing his/her state 
of health at the moment (best value=1; 
worst value=5).205 The single index 
score (15D score) represents the overall 
HRQoL on a 0–1 scale (1=full health, 
0=being dead) and the dimension level 
values reflect the goodness of the levels 
relative to no problems on the dimension 
(=1) and to being dead (=0). They are 
calculated from the questionnaire using 
a set of population-based preference or 
utility weights. Mean dimension level 
values are used to draw 15D profiles for 
groups. A difference in the 15D score of 
±0.015 is clinically important.206 Please 
see Appendix 1 for the 15D questionnaire 
form.
2.4.4 Modified Rankin Scale
2.4.4.1 History
The modified Rankin Scale, as the name 
implies, was developed from the Rankin 
Scale, originally introduced by Dr. Jon 
Rankin in 1957, by Dr. van Swieten et 
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al. in the 1980s.207 The original scale, 
numbered from 1 to 5, was generated 
to measure the degree of disability and 
dependence after a stroke or any other 
neurological disease. The adjustment 
made in the 1980s was the addition of 
grade 0 to represent patients who lack 
symptoms and are independent in the 
activities of daily living. Later in 2005, 
grade 6 was also added to represent the 
deceased patients.208 
2.4.4.2 Use in modern research
The mRS is the most commonly used 
indicator of functional outcome after 
stroke.208 In its current form, it consists 
of an ordinal classification, in which 0 
represents patients with no symptoms 
and total independence in daily activities; 
1 patients with no significant disability, 
who are able to carry out all usual 
activities, despite some symptoms; 2 
patients with slight disability, who can 
attend their daily activities without 
assistance, but who are unable to carry 
out all previous, premorbid activities; 3 
patients with moderate disabilities, who 
require some help with daily activities 
but can walk unassisted; 4 patients 
with moderately severe disability, who 
cannot attend their own bodily needs 
without assistance and are unable to 
walk unassisted; 5 patients with severe 
disability, who require constant nursing 
home care and attention, who are 
bedridden; and 6, deceased patients.207 
mRS is an easy end-point variable in 
neurosurgical research, however, critique 
about the interobserver reliability has been 
expressed by the scientific community.209 
Various educational materials have 
been developed to unify the grading 
especially in the mid-grades, in which 
the differences are substantially smaller 
than in the end-points of the spectrum.210 
Additionally, since the modern outcome 
research is turning more toward HRQoL 
instruments, the developers of mRS have 
constructed a new version of the original 
grade, the mRS-9Q, which translates 
HRQoL-style questions (yes/no) into a 
single mRS grade.211 Although promoted 
as easy-to-administer, the new grade has 
not, at least yet, proved its popularity 
among researchers. 
2.4.4.3 Dichotomization
Dichotomizing a variable means creating 
two categories into which the grades 
from the original variable fall. This is 
rather common in clinical research, as 
it for instance eases the presentation 
of data, the interpretation of the results 
and the conduction of statistical analyses. 
However, dichotomization comes with a 
cost, as it creates a loss of information 
inside the dichotomous grade, and if 
the cut-off point is incorrectly chosen 
might falsify results.212 It can become 
especially problematic with follow-up 
studies evaluating the treatment effect, in 
which the pursued outcome is getting the 
patient from the unfavorable outcome 
group into the favorable outcome 
group. In this method of evaluating the 
outcome, we fail to notice improvement 
inside the dichotomous grade, which 
might be clinically relevant (Figure 15). 
The dichotomization of mRS was first 
used in an acute stroke NINDS (National 
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Institute of Neurologic Diseases and 
Stroke) tissue plasminogen (tPA) trial 
in 1995, in which the grade was cut 
into a favorable outcome (mRS 0–1) 
and an unfavorable outcome (mRS 
2–5).213 Ever since the NINDS tPA trial, 
dichotomization has also become more 
common in other neurological and 
neurosurgical studies, with varying 
cut points. Dichotomization does 
have multiple statistical advantages.214 
Regarding mRS, it can compensate for 
the possible issues with interobserver 
variability, especially in the mid-range 
of the scale.212 Owing to its nature as a 
purely clinical grading system, the cut-off 
is often chosen to stand at the border of 
functional independence / dependence.215 
By definition, in mRS 1, the patients can 
still carry on with their previous activities, 
whereas in mRS 2 they cannot. Secondly, 
the mRS 2 patients can still look after 
their affairs without assistance when 
compared to mRS 3, and therefore 
mRS grades ≤2 are defined to indicate 
functional independence.216 However, the 
cut-off points vary between studies, with 
the rationale behind the decision rarely, 
if ever, reported. On the other hand, 
outcomes are rarely dually distributed, 
complicating the determination of a 
‘’good’’ or ‘’bad’’ outcome. This has been 
Figure 15A. Example of typical dichotomization of body mass index (BMI): dichotomization of a 
continuous variable with a commonly recognized cut point. 
Figure 15B. Illustration of the problems related with clinical outcome grades and their statistical 
handling. The gaps between grades are irregular, which complicates the interpretation of results, 
especially if the cut point is incorrectly chosen. For instance, if the exemplary cut point between 
mRS 2 and 3 is chosen, but the largest clinical improvement is actually between grades 1 and 2, 
this effect remains unmasked (loss of information inside the grade). Secondly, if the cut-off point 
is chosen to be in-between grades very close to each other, for instance grades 0 and 1, there is 
a higher risk that the improvement / decline between the grades is actually owing to coincidence 
(bias).
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tried to be solved by numerous methods 
which, rather than comparing two fixed 
classes to one another, attempt to better 
take into account the movement across 
the whole scale.215, 218 Another issue with 
mRS dichotomization is that the grades 
are not evenly distributed concerning the 
functional outcome, meaning that the 
distance between patients in mRS 4 and 
5 is reportedly longer than for instance 
between mRS 0 and 1 patients in terms 
of physical functioning.219 Therefore, as 
mentioned, the choice of cut point should 
support the severity of the disease and 
the point where the treatment effect is 
anticipated.217 
2.4.5 Factors affecting HRQoL 
The relationship between HRQoL and 
functional outcome is well distinguished 
in the literature.220, 221 After the transient 
impact of morbidity starts to diminish 
and patients’ healing progresses, 
functional outcome improves together 
with HRQoL.221 This postmorbid 
functional, psychological and social 
improvement can take many years, 
and the positive effect a close-to-death 
accident has on the appreciation of life 
can be influential even decades after.221 
Studies on SAH patients have reported 
rather significant numbers of patients 
who have not been able to return to work, 
as many as two-thirds of the patients 
even years after the incident.222, 223 As 
discussed earlier, the impact returning 
to work has on QoL and life satisfaction 
cannot be understated.224 In a prospective 
cohort study of 22,000 Finnish working-
age people in a 6-year follow-up, the most 
common reasons for work disability 
were musculoskeletal and depressive 
symptoms, and a decrease in vitality.225 
However, in the existing literature about 
stroke patients, only one study has found 
an association between depression and 
inability to return to work.226 In a Finnish 
patient sample of aneurysmal SAH 
(aSAH) patients, the factors associated 
with long-term employment status after 
SAH were age inversely, higher levels of 
education and lower levels of self-rated 
impairments.227 Additionally, impaired 
mental health and functioning have 
been linked to decreased HRQoL in 
previous studies on patients with SAH 
or ICH.228, 229 This connection has been 
explained with damage to the reticular 
formation and related structures of the 
brain controlling arousal, as well as 
association to sleeping disorders, stress, 
pain and chronic illnesses.230, 231  
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3 AIMS OF THE STUDY
1. To evaluate the HRQoL in patients treated for their AVMs and dissect which 
factors affect this long-term outcome.
2. As smoking is one of the most recognized cerebrovascular risk factors, to evaluate 
its potential association with brain AVMs.
3. To investigate how an objective outcome instrument (mRS) mirrors the subjective 
HRQoL and how this could affect the interpretation and statistical handling of 
the measures. 
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4 PATIENTS AND METHODS
4.1 Patients and data
During the time of the making of this 
thesis, the Helsinki AVM Database 
included 805 patients with brain AVM 
admitted to the HUH Department 
of Neurosurgery between 1942 and 
2014. The database has been collected 
retrospectively using medical records 
and images. The AVM diagnosis was 
based on angiography (DSA and/or 
computed tomographic angiography 
(CTA)). HRQoL questionnaires were 
sent in 2016 to all living patients 
(n=432) in the database, older than 
18 years of age. The letter contained 
separate questions regarding symptoms, 
comorbidities, lifestyle, and self-
sufficiency/independence, along with 
the 15D HRQoL questionnaire. Of them, 
325 (75.2%) answered. The anatomical 
features of the AVMs were evaluated 
based on CT and/or MR imaging and 
angiography. The location was classified 
as either cerebellar, frontal, occipital, 
parietal, temporal, or deep. The operated 
patients had follow-up angiograms 
performed immediately after the surgery 
to rule out/detect residual AVM. The 
lesions were classified in SMG, which 
were converted into SPC, based on 
their preoperative characteristics.87, 111 
The functional outcome of the patient, 
measured with mRS, was assessed based 
on the survey data and clinical records. 
4.1.1 Study I
Of the 325 (75.2%) patients who answered 
the original HRQoL questionnaire, the 
cohort was further specified to consist 
of patients with the complete obliteration 
of the AVM (n=262), regardless of the 
treatment modality. This was done to 
minimize the biases owing to patient 
selection into each treatment modality, 
since with modern knowledge the best 
possible modality is chosen for the 
patient, causing inevitable selection 
bias. The general population sample was 
obtained from the HUH catchment with 
the Finnish Health 2011 Survey.232
4.1.1.1 Engel classification for 
postoperative epilepsy
In Study I, we used the Engel classification 
for postoperative epilepsy, which has 
been proposed in 1993 by neurologist 
Jerome Engel.233 It has become the most 
used scale demonstrating the outcome 
after epileptic surgery.234 The grading is 
based on the self-reported symptomalogy 
of the patient. By definition, Engel class 
I patients are free of disabling seizures; 
class II patients have disabling seizures 
rarely, during a period of at least two years; 
class III patients experience a notable 
improvement and seizure reduction 
for prolonged periods, however for less 
than two years; and class IV in which 
patients have not noticed any reduction 
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in the seizures, or some reduction but 
not notable improvement.233 
4.1.2 Study II
Patients were derived from the Helsinki 
AVM HRQoL database. Patients younger 
than 18 years of age during admission 
were excluded from the study to 
ascertain a sufficient exposure time to 
cigarette smoking before admission. 
This meant excluding 48 patients, 
leaving the final study cohort of 277 
patients. The HRQoL letter included 
a panel of questions about lifestyle 
and demographic, socioeconomic and 
behavioral aspects. The letter included 
questions about smoking status at the 
time of answering the questionnaire 
(current/ex/never-smoker), the number 
of cigarettes smoked daily, and the length 
of smoking history in years. These data, 
supplemented with the data from clinical 
records, were used to determine patients 
who were smoking during admission or 
during the follow-up period and had a 
smoking history of at least one year. The 
same criterion of the length of smoking 
was used as an inclusion criterion for 
the analysis of the smoking prevalence, 
thus, the patients had to have at least 
one year of a smoking history before the 
admission. When the clinical records 
were explored, eight more patients were 
found who had smoked more than one 
year continuously before their diagnosis, 
and they were classified as on-admission 
smokers, and included in the prevalence 
analyses. Despite the exploration of 
clinical records, a total of 65 (24%) 
patients who were smoking at the time 
of the questionnaire or had a smoking 
history had not reported the length of their 
smoking history and could not reliably be 
classified as on-admission smokers. This 
was to provide a conservative estimation 
and to avoid exaggerating the prevalence 
of on-admission smokers. However, 
presumably some of these patients 
were smoking already during their 
admission. For the cross-tabulations of 
the demographic characteristics of the 
study cohort, patients had to have at least 
one year of continuous smoking during 
the follow-up period to be regarded as 
ever-smokers. Only one patient had 
smoked less than one year continuously 
and was classified as a never-smoker. The 
matched prevalence was obtained from 
the statistics of the National Institute of 
Health and Welfare in their yearly random 
sample of the Finnish population.235 
4.1.3 Study III
Of the 325 patients who answered the 
HRQoL letter, only two had an mRS 
5 functional status in 2016. Owing to 
the scarcity of these patients, they were 
excluded from the final study cohort, 
leaving 323 patients for the analyses. 
Since the main idea of the study was to 
illustrate how the different mRS grades 
reflect HRQoL, there was no need for 
making further specifications to the 
mRS cohorts, since in fact these factors 
(such as treatment modality) should not 
affect the mRS classification directly. Two 
patients (0.9%) had not filled in the whole 
15D questionnaire, and therefore they 
were excluded from the analyses of the 
dimensions in question. The 15D data 
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for the reference group came from the 
Finnish National Health 2011 Survey, 
which represents Finnish citizens over 
18 years of age collected with random 
sampling from the general population. 
This group was selected from the 
HUH catchment area (n=1350) to rule 
out possible biasing factors, such as 
cultural differences. For the literature 
review, we collected all the AVM studies 
from the previous five years which 
had used dichotomized mRS in their 
analyses. This was done by searching 
PubMed with the search terms ‘’AVM’’, 
‘’arteriovenous malformation’’, ‘’mRS’’, 
‘’modified Rankin Scale’’ and ‘’functional 
outcome’’ on 2 August 2020. Studies 
which had reported the dichotomization, 
follow-up time and number of patients 
were included. We excluded studies with 
pediatric or elderly AVM patients. The 
15D data for the general population came 
from the National Health 2011 Survey 
representing the Finnish population 
aged over 18.232
4.2 Statistical methods
4.2.1 Studies I and III
We used the generic, self-administered 
15D HRQoL instrument to illustrate the 
differences in the long-term HRQoL.205 
The results obtained with the 15D were 
compared with those of the general 
population (n=1347) standardized for age 
and gender, and obtained from the HUH 
catchment area of the Finnish Health 
2011 Survey.232  The statistical analysis 
was performed using the SPSS for Mac 
statistical software version 24 (SPSS, 
Inc., Chicago, IL, USA). Subgroup 15D 
analyses were conducted for the variables 
of SPC (for groups SPC A, B, and C), 
number of bleeding episodes (for zero, 
one, or multiple bleeding episodes), 
epilepsy (groups Engel I and II–IV), 
mRS (grades 0–4 independently) and 
lesion’s anatomical location (classified 
as mentioned above). Quantitative 
variables were handled as continuous 
or ordinal, with the exception of the 
number of bleeding episodes variable, for 
which the patients with multiple (two or 
more) bleeding episodes comprised their 
own group, compared to patients with 
only one or no bleeding episodes. The 
statistical significance of the differences 
in the mean HRQoL scores and its 
dimensions were tested by independent 
samples t-test or analysis of covariance 
(ANCOVA) (age-standardized), followed 
by Bonferroni-corrected post-hoc tests. 
The variance in the 15D scores was 
explained by a Tobit regression model.236 
The model was deemed suitable for two 
reasons. First, the distribution of the 
dependent variable (15D score) was not 
normal but skewed and censored at 0 
and 1 (the range of the scores is 0–1) and, 
second, a substantial proportion of the 
observations was at the upper limit of 
1 (19.8%). The Tobit regression model 
was run by LIMDEP version 7.0 (Greene 
WH. LIMDEP Version 7.0: User’s manual, 
revised version. Econometric Software, 
Inc.: New York, 1998). Variables included 
in the regression model were patient’s 
age at admission, sex, bleeding status at 
admission, SPC, and refractory epilepsy. 
The reference groups for the nominal 
variables in the model were male sex, 
SPC group B, and the group with no 
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bleeding episodes. Two-sided p-values 
<0.05 were considered statistically 
significant. 
4.2.2 Study II
Because a large proportion of all AVMs 
in Finland have been treated in our 
clinic in Helsinki, we compared the on-
admission smoking prevalence in AVM 
patients to that of the general population. 
AVM admission year and sex-matched 
prevalence of smokers in the general 
population was derived from statistics 
of the National Institute for Health and 
Welfare that includes yearly random 
samples of the general population.235e> 
The final age group–specific general 
population data included the same 
proportion of men and women as the 
AVM data. In addition, the data collection 
years had the same distribution as AVM 
patients’ admission years. This was 
done to take into account the changes 
in smoking prevalence over the data 
collection period. Logit transformation of 
proportions and Students t distribution 
were used to calculate the 95% CIs for 
prevalence estimates. We categorized 
smokers to light (less than 10 cigarettes 
per day), moderate (from 10 to 19 
cigarettes per day), and heavy smokers 
(20 or more cigarettes per day). Difference 
between variables with two categories 
was tested with Fisher’s Exact test with 
two-sided p-values, and variables with 
three categories with Kruskal–Wallis H 
test. For normally distributed continuous 
variables, we used independent samples 
t test. Mann–Whitney U test was used 
for the analyses of the differences 
in the number of daily cigarettes for 
the following grouping variables: sex, 
age group at admission, age group 
in 2016, admission decade, AVM size 
(descriptive: small being 0–1 inches vs. 
medium 1–2 inches vs. large >2 inches), 
pattern of venous drainage (superficial 
vs. deep vs. superficial and deep), AVM 
location (deep vs. cortical vs. cerebellar), 
number of AVM hemorrhage (zero vs. 
one bleeding episode vs. more than 
one), and mRS in 2016. P-values <0.05 
were considered statistically significant. 
Statistical analyses were conducted 
using Stata/MP15.1. Stata Corp, College 
Station, TX, USA and A.P using IBM 
SPSS Version 24.0.0.0 for Mac (SPSS, 
Inc., Chicago, IL, USA).
4.3 Standard protocol 
approvals
All individual participants gave informed 
consent for the use of questionnaire data 
in the studies in this thesis project. The 







The mean age during admission was 
35.2 years (SD ±16.4yr) and in 2016 52.8 
years (SD ±15.3yr).I The mean follow-up 
time from the diagnosis to 2016 was 17.6 
years (SD ±12.0 yr). Table 7 collects the 
demographic characteristics of the cohort 
of Study I. Comorbid conditions were 
reported by 191 patients (72.9%); the most 
common diagnosis was hypertension 
(26.7%), followed by epilepsy (14.5%) 
and transient ischemic attack (9.5%).I 
The AVM had affected the vocational 
selection of 44 patients (16.8%). Forty-
one patients (15.6%) had retired due to 
the lesion and 59 patients (22.5%) due 
to age.
There were 33 patients (12.6%) with 
associated aneurysms. I The rest of the 
anatomic characteristics are given in Table 
8.  A total obliteration was achieved in all 
patients (the criterion for the cohort), and 
this was accomplished with neurosurgery 
in 249 patients (95.0%). Embolization was 
included in the treatment plan in 25 SPC 
A patients, 9 SPC B patients and 5 SPC 
C patients; and SRS in 5 SPC A, 9 SPC 
B and 5 SPC C patients. II Of the 137 SPC 
A patients, 135 were operated on (98.5%), 
of 80 SPC B patients 73 were operated on 
(91.3%) and of 42 SPC C patients 41 were 
operated on (97.6%). This is mostly due 
to the fact that the criterion for inclusion 
in this study was the total occlusion of 
the lesion, for which surgery is the most 
effective method. 
5.1.2 Study II
The mean age on admission was 38.8 
years (SD ±14.8yr) and in 2016 57.0 
years (SD ±14.5yr).II The demographics 
and anatomic lesion characteristics are 
reported in Table 9. Sixty-four (23.1%) 
patients were admitted before the 1990s, 
66 (23.8%) during the 1990s, most 
patients were admitted during the 2000s 
(n=100, 36.1%) and 47 (17.0%) patients 
after 2010.II 
5.1.3 Study III
The mean follow-up time from admission 
to 2016 was 19.4 years (SD=±13.8 years) 
(Table 8). All patients had had at least 
one-year follow-up before returning the 
questionnaire. The longest follow-up 
time was 63 years. Table 10 illustrates 
the basic demographic characteristics of 
each mRS cohort. 
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Table 7. Demographic characteristics of Study I.
n %
Sex Female 127 48.5
Male 135 51.5
Total 262 100.0





Education Basic level 59 22.5
Vocational 61 25.3




Table 8. Anatomic characteristics AVMs in Study I. Infratentorial lesions include both brainstem and 
cerebellar lesions.
n %











Ruptured AVM No 74 28.2
Yes 187 71.9
Single bleeding ep 162 61.8




Table 9. Demographic and anatomic characteristics of Study II.
n %
Sex Female 136 49.1
Male 141 50.9
Total 277 100.0
Rupture status Ruptured 179 64.6
Unruptured 98 35.4
Total 277 100.0
Operated Yes 224 80.9
No 53 19.1
Total 277 100.0
AVM size Small (0-1 inch) 131 47.3
Medium (1-2 inch) 114 41.2
Large (>2inch) 32 11.6
Total 277 100.0
Table 10. Demographic characteristics of study III.
Females AVM fully 
occluded













N=154 61 (40%) 128 (82%) 52.5 SD=±16.1 32.4 SD=±15.3 18.9 SD=±13.0 1.7-63
mRS 1
N=78 44 (56%) 62 (80%) 50.9 SD=±16.4 35.8 SD=±17.4 22.0 SD=±15.6 1.2-62
mRS 2
N=39 20 (51%) 28 (72%) 56.5 SD=±16.5 32.1 SD=±13.8 16.5 SD=±11.8 1.3-52
mRS 3
N=32 21 (66%) 28 (88%) 56.8 SD=±15.0 38.0 SD=±18.8 19.6 SD=±11.7 1.3-50
mRS 4
N=20 13 (62%) 18 (86%) 67.1 SD=±8.9 48.7 SD=±18.3 23.5 SD=±20.0 1.4-59
Total
N=323 159 (49%) 262 (81%) 54.0 SD=±16.2 34.7 SD=±16.6 19.4 SD=±13.8 1.2-63
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5.2 Long-term health-
related quality of life 
in 262 patients
Compared to the general population 
using age- and sex-standardization, AVM 
patients with totally occluded lesions 
(n=262) had impaired HRQoL, with 
a mean difference (MD) in 15D index 
score of 0.047 (95% CI: 0.032–0.062, 
p<0.0001). This is illustrated in the 15D 
profile in Figure 16, which also separates 
the independent dimensions. The largest 
impairments were in the dimensions of 
usual activities, movement, mentality 
and sexual activity.I  
5.2.1 SPC classification and HRQoL
In the AVM patients with totally occluded 
lesions, the patients with SPC A type 
lesions had a significantly better HRQoL 
in long-term follow-up compared to 
the patients with SPC C type lesions 
(MD=0.0646, 95% CI: 0.018–0.112, 
p=0.0031). Regarding the 15D index 
score, SPC B and SPC C did not differ 
statistically significantly (MD=0.0442, 
95% CI: -0.006–0.095, p=0.109), however, 
there were significant differences in the 
individual dimensions (vision, speech, 
discomfort) as illustrated in Figure 17. 
The characteristics of patients in SPC 
classes are given in Table 11.
Figure 16. 15D profiles of AVM patients with totally occluded lesions (n=262) compared to that of 
the general population (n=1347) using age and sex standardization. Asterisks indicate statistical 
significance in the dimension in question, tested with the independent samples t test. Patients with 
missing values in the dimension in question were not included in the analysis of that dimension.
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5.2.2 Number of bleeding episodes
Multiple bleeding episodes were 
associated with a decreased HRQoL, 
however, this difference, compared 
to a single bleeding episode or no 
hemorrhagic events, did not yield 
statistical significance.I The MD of the 
15D index score between a single bleeding 
episode and no bleeding episodes was 
0.031 (95% CI: -0.007–0.069, p=0.146), 
between a single bleeding episode and 
multiple (>1) episodes 0.03 (95% CI: 
-0.029–0.089, p=0.647), and between 
no bleeding episodes and multiple 
bleeding episodes 0.061 (95% CI: -0.001–
0.124, p=0.057).I In the comparisons 
of the individual dimensions, there 
were statistically significant differences 
between the group of patients with 
no bleeding episodes and the group 
with multiple bleeding episodes in the 
dimensions of vision and usual activities 
(Figure 18). 
5.2.3 Postoperative epilepsy 
and HRQoL
Postoperatively, there were 38 patients 
(14.5%) who had Engel class II–IV 
epileptic seizures at the time of the survey. 
The dimensions which were impaired 
the most were mental functioning, usual 
activities and vitality.I Compared to Engel 
class I patients, the MD was 0.061 (95% 
CI: 0.023–0.100, p=0.00017). These 15D 
HRQoL profiles are illustrated in Figure 
19.
Figure 17. Comparison of 15D HRQoL profiles according to SPC classes. Statistical significance in 
the individual comparisons between classes in each HRQoL dimension is marked with asterisks. The 
comparison of index scores (mean 15D score) and the statistical significance of this comparison is 
reported in the table in the upper-right corner. One patient with missing SPC grade was excluded 
from these analyses.
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SPC x n/o bleeding episodes, 
Fisher’s Exact test, 2-sided 
p=0.014
Preoperative SPC 0, n (%) 1, n (%) >1, n (%) Total, n (%)
A 29 (39.2) 98 (60.5) 12 (48.0) 139 (53.3)
B 31 (41.9) 43 (26.5) 6 (24.0) 80 (30.7)
C 14 (18.9) 21 (13.0) 7 (28.0) 42 (16.1)
Total (%) 74 (28.2) 162 (61.8) 25 (9.5) 261 (99.6)
SPC A SPC B SPC C ANOVA
Mean (SD) age at 
admission, years
36.7 (17.2) 33.1 (16.1) 33.6 (13.8) F(2, 258)=1.45, 2-sided p=0.237
Mean (SD) age  
in 2016, years
54.4 (15.7) 50.4 (15.4) 51.9 (13.2) F(2, 258)=1.86, 2-sided p=0.158
Fisher’s exact test, 2-sided p
Females (%) 70 (50.4) 35 (43.8) 22 (52.4) P=0.575
Retired due to AVM 
(%)
16 (11.5) 12 (15.0) 13 (31.7) P=0.018
Symptoms due to 
AVM
85 (61.2) 54 (67.5) 34 (81.0) P=0.051
Treatment included:
Surgery (%) 135 (97.1) 73 (91.3) 41 (97.6) P=0.130
Embolization (%) 25 (18.0) 27 (33.8) 26 (61.9) p<0.0001
Radiosurgery (%) 5 (3.6) 9 (11.3) 5 (11.9) P=0.038
mRS at last follow-up χ2(2,255) = 10.06, p=0.0070
0 (%) 47 (35.1) 28 (35.0) 8 (19.5)
1 (%) 39 (29.1) 20 (25.0) 7 (17.1)
2 (%) 31 (23.1) 19 (23.8) 13 (31.7)
3 (%) 11 (8.2) 8 (19.5) 9 (22.0)
4 (%) 5 (3.7) 5 (6.3) 3 (7.3)
5 (%) 1 (0.7) 0 (0) 1 (2.4)
ANOVA = analysis of covariance
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Figure 18. Comparison between patients with no bleeding episodes from the AVM, patients with 
a single bleeding episode and patients with more than one (multiple) bleeding episodes. The only 
statistically significant differences were in the dimensions of vision and usual activities between 
patients with no bleeding episodes and patients with multiple bleeding episodes. Despite the 
statistical non-significance of the rest of the dimensions, there is a clear trend toward worse HRQoL 
values owing to multiple bleeding episodes.
Figure 19. Comparison between patients with refractory epilepsy (Engel II–IV) and patients without 
epilepsy (Engel I). By definition, Engel class I patients are free of disabling seizures. For more 
specific definitions, please see section 2.1.6.7.
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5.2.4 Location of the lesion
The HRQoL did not differ regarding 
the different cortical locations. However, 
there was a significant decrease in the 
total 15D score of the patients with 
deeply located lesions compared to the 
frontal (MD 0.086, 95% CI: 0.013–0.159, 
p=0.008), parietal (MD 0.094, 95% CI: 
0.014–0.174, p=0.007), and temporal 
(MD 0.087, 95% CI: 0.004–0.165, 
p=0.016) AVMs. Also, decreased mental 
functioning was associated with deeply 
located AVMs (mean 0.622, SD ±0.238) 
compared to those with frontal (MD 
0.232, 95% CI: 0.079–0.385, p<0.0001), 
parietal (MD 0.227, 95% CI: 0.060–0.395, 
p=0.001), temporal (MD 0.229, 95% CI: 
0.065–0.394, p=0.001), and cerebellar 
(MD 0.192, 95% CI: 0.001–0.383, p=0.047) 
lesions. Another dimension with 
decreased values among the patients with 
deep AVMs was the ability to continue 
previous usual activities (mean 0.689, 
SD ±0.254 for deep AVMs) compared to 
those with frontal (MD 0.140, 95% CI: 
-0.023 to 0.303), parietal (MD 0.180, 95% 
CI: -0.002 to 0.359), and temporal (MD 
0.174, 95% CI: -0.001 to 0.349) AVMs. 
These differences, however, did not reach 
statistical significance. 
5.2.5 Functional outcome and HRQoL
The effect functional outcome, measured 
with mRS, has on long-term HRQoL was 
evaluated in patients with totally occluded 
lesions.I At the last follow-up there were 
83 patients (31.7%) in mRS 0, 67 in mRS 
1 (25.6%), 63 in mRS 2 (24.0%), 28 in 
mRS 3 (10.7%), 13 in mRS 4 (5.0%) and 
2 in mRS 5 (0.8%). Higher mRS scores 
(decrease in functional outcome) were 
associated with decreased HRQoL: mRS 
score of 0 (mean 15D 0.938, SD ±0.082, 
mean age 49 years), mRS score of 1 
(mean 0.895, SD ±0.118, mean age 53 
years), mRS score of 2 (mean 0.869, SD 
±0.087, mean age 52 years), mRS score 
of 3 (mean 0.771, SD ±0.129, mean age 60 
years), and mRS score of 4 (mean 0.721, 
SD ±0.116, mean age 61 years). There 
was no statistically significant difference 
in the mean 15D score between the 
patients in mRS 0 and mRS 1, nor in 
mRS scores of 1 and 2 or scores of 3 
and 4. All other scores reached statistical 
significance in the pairwise comparisons 
of total 15D score (p<0.002). There was 
a significant difference between the 
different mRS grades in the physical 
dimensions (movement, usual activities 
and sexual activity). The mental domains 
overlapped in all the other grades except 
mRS 0.
5.2.6 Multivariate model predicting 
long-term HRQoL in 
treated AVM patients
We used Tobit regression to estimate 
the 15D index (total) score based on 
age, sex, refractory epilepsy, SPC, and 
number of bleeding episodes. We found 
a significant regression equation (F7,251= 
9.37, p<0.0001), with an R2 of 0.207: 
patient’s index 15D score = 0.8497 – 
0.00234(age in years, p<0.0001) + 0.0365(if 
male, p<0.0044) – 0.0530(if Engel II–IV, 
p<0.0034) – 0.0402(if SPC C, p<0.0388) 
– 0.0548(if multiple bleeding episodes, 
p<0.0217). There was no statistically 
significant difference in the equation 
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between the patients having SPC A or 
SPC B lesions. 
5.3 The association between 
smoking and AVM patients
In the HRQoL questionnaire, we inquired 
about the smoking habits of AVM 
patients. These data were supplemented 
with the exploration of clinical records. 
Despite this, the length of smoking 
history could not be determined for 66 
patients. Table 12 illustrates the smoking 
statistics derived from the questionnaire 
supplemented with clinical records. 
When taking into account the patients 
of all ages, the proportion of smokers in 
AVM patients was 48% (95% CI: 41–55%) 
during admission, whereas in the age-, 
sex- and admission year–matched general 
population 19% (95% CI: 16–21%). The 
difference increased in the older patient 
groups: in the age group of 20–34 years, 
the mean percentage of smokers in 
AVM patients was 33% (95% CI: 21–
49%), whereas the general population 
mean was 20% (95% CI: 18–23%); age 
group 35–44 years, AVM patients’ mean 
52% (95% CI: 38–67%) and population 
mean 20% (95% CI: 17–23%); age group 
45–54 years, AVM patients’ mean 57% 
(95% CI: 41–72%) and population mean 
20% (95% CI: 17–23%); age group 55–64 
years, AVM patients’ mean 53% (95% CI: 
36–70%) and population mean 16% (95% 
CI: 14–20%); and age group 65–77 years, 
AVM patients’ mean 73% (95% CI: 46–
90%) and population mean 7% (95% CI: 
5–9%).II These differences are illustrated 
in Figure 20. 
In the univariate analyses, females 
smoked less daily (mean 11.3 cigarettes, 
SD ±8.1) than male AVM patients (mean 
14.0 cigarettes, SD ±9.2), p=0.020). A 
small AVM size was associated with 
less cigarettes smoked daily (mean 
11.6 cigarettes, SD ±8.5) compared to 
the patients with medium (mean 13.8 
cigarettes, SD ±9.6) or large AVMS (mean 
13.9, SD ±6.0), however, these differences 
did not reach statistical significance. All 
the patients who still continued smoking 
in 2016 despite AVM diagnosis / treatment 
(n=66) were mostly either moderate 
(31.8%) or heavy smokers (34.1%).II 
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Table 12. Smoking statistics derived from the HRQoL questionnaire sent in 2016, supplemented with 
data from clinical records. The categories for the number of cigarettes smoked daily were as follows: 
less than 10 cigarettes for light smokers; 10–19 cigarettes per day for moderate, and 20 or more 
cigarettes for the heavy smokers.
N %
Smoking before admission Yes 105 37.9
No 106 38.3
Not known 66 23.8
Total 277 100
Smoking ever Never 98 35.4
Current or ex 179 64.6
Total 277 100
Smoking in 2016 Yes 66 23.8
No 211 76.2
Total 277 100
Number of daily cigarettes Light smoker 41 22.9
Moderate 57 31.8
Heavy 61 34.1
Total (of all ever-smokers) 159 88.8
Figure 20. Prevalence of smokers in AVM patients and the general population, matched for age, sex 
and admission year. Prevalence is reported with the percentage of smokers / 100 (i.e., 30% = 0.3). 
Blue bars represent AVM patients and green bars (THL) the matched general population. 95% CIs 
are reported with the whiskers. The figure was drawn with the conservative estimation, meaning 
that the patients whose length of smoking could not be reliably estimated (n=66) were classified as 
non-smokers. Of them, 11 were smoking in 2016 and 54 were ex-smokers.
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5.4 Health-related quality 
of life and modified 
Rankin Scale 
5.4.1 Comparison of mRS grades 
and the general population 
There were 154 AVM patients with a 
functional outcome of mRS 0 in 2016, 
and their mean 15D score was 0.954 (SD 
±0.060). Compared to the age- and sex-
standardized general population (mean 
15D index score 0.927, SD ±0.028), they 
had a better 15D index score and this 
difference was statistically significant 
(p<0.0001). These profiles are illustrated 
in Figure 21. Patients with an mRS 
1 functional outcome in 2016 (mean 
15D index score 0.844, SD ±0.100) had 
worse HRQoL than the age- and sex-
standardized general population (mean 
15D index score 0.927, SD ±0.021), and 
this difference was statistically significant 
(p<0.0001). These profiles are illustrated 
in Figure 22. 
5.4.2 Comparing mRS grades 
to each another
All of the mRS grades included in this 
study were compared to each other 
regarding HRQoL in 2016 measured with 
15D. The grades differed significantly 
from each other regarding their 15D 
index score, with the exception of mRS 
1 (mean = 0.840, 95% CI: 0.821–0.860) 
and mRS 2 (mean = 0.841, 95% CI: 0.813–
0.868). Mobility was the only individual 
dimension which was able to distinguish 
the grades from each other. The 
estimated mean values for the mobility 
dimension were 0.968 (95% CI: 0.946–
0.991) for mRS 0 patients, 0.885 (95% CI: 
0.853–0.916) for mRS 1, 0.783 (95% CI: 
0.738–0.827) for mRS 2, 0.662 (95% CI: 
0.613–0.711) for mRS 3, and 0.311 (95% 
CI: 0.246–0.376) for mRS 4. Figure 23 
illustrates the comparison between 
mRS grades. Figure 24 illustrates the 
comparison of 15D scores between mRS 
0 and mRS 1 AVM patients using age 
and sex standardization. 95% CIs are 
included in the figure.  
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Figure 21. Patients with mRS 0 functional status in 2016 compared to the age- and sex-standardized 
general population regarding their answers to the 15D HRQoL questionnaire. The difference between 
the index 15D scores was statistically significant, as well as the individual dimensions marked with 
asterisks.
Figure 22. Comparison of patients with mRS 1 functional status in 2016 and the general population 
(age- and sex-standardized) regarding HRQoL measured with 15D. The difference between index 15D 
was statistically significant, as well as the individual dimensions marked with asterisks. 
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Figure 23. Comparison of mRS grades to each other using age and sex standardization. In the 
dimension of usual activities, all the grades, except mRS 1 and 2, differed statistically significantly 
from one another: the estimated means for this dimension were 0.959 (95% CI: 0.932–0.986) for 
mRS 0 patients, 0.790 (95% CI: 0.753–0.828) for mRS 1, 0.730 (95% CI: 0.676–0.783) for mRS 2, 
0.561 (95% CI: 0.503–0.620) for mRS 3 and 0.283 (95% CI: 0.206–0.360) for mRS 4. All the mRS 
grades differed statistically significantly from each other regarding the index 15D score, except mRS 
1 and mRS 2.
Figure 24. Comparison of the 15D scores in mRS 0 and mRS 1 AVM patients, age- and sex-
standardized. 95% CIs are illustrated with dots, UI = 95% CI upper margin, LI = 95% CI lower margin.
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5.4.3 Literature review 
All the 17 AVM follow-up studies using 
mRS dichotomization published within 
the previous 5 years are represented in 
Table 13. Nine studies (52.9%) categorized 
favorable outcomes as mRS 0–2 and 
unfavorable as mRS 3–5.86, 120-123, 130, 131, 237, 238 
The rest (47.1%) used the lower cut point 
of mRS 1.50, 82, 85, 118, 119, 239-241 All the studies 
with either high-grade or brainstem 
AVMs used the higher cut point.86, 122, 238 
In the studies using the cut point of mRS 
2, the mean follow-up time was 3.4 years 
(SD ±3.1y), and for the studies using the 
cut point mRS 1, 2.4 years (SD ±1.9y). 
Table 13. AVM studies using dichotomized mRS published in the previous 5 years. Studies with 
low-grade or cerebral AVMs had the tendency of using a lower cut point, whereas in studies with 
infratentorial, deep or high-grade AVMs the higher cut point was chosen.







Wang et al. (2020)131 4.5 0-2 258 Low-grade, SMG I-II AVMs
Pulli et al. (2019)82 5.0 0-1 318 Cerebral AVMs
Iosif et al. (2019)130 0.5 0-2 73 Low-grade AVMs
Kocer et al. (2019)238 0.5 0-2 31 High-grade, SM III-V AVMs
Jean et al. (2019)239 1.6 0-1 86 90% lobar AVMs
Madhugiri et al. (2018)122 4.0 0-2 39 Brainstem AVMs
Hung et al. (2018)240 3.0 0-1 137 SMG II AVMs
Pohjola et al. (2018)121 9.7 0-2 38 Posterior fossa AVMs
Mascitelli et al. (2018)123 2.0 0-2 241 Eloquently located AVMs
Lin et al. (2017)237 1.6 0-2 184 39% eloquently located AVMs
Schramm et al. (2017)50 5.3 0-1 288 Cerebral AVMs
Morgan et al. (2017)119 1.0 0-1 675 SMG I-III AVMs
Bervini et al. (2017)241 1.0 0-1 769 87% supratentorial
Tong et al. (2017)120 6.4 0-2 181 Cerebellar AVMs
Javadpour et al. 
(2016)85 
0.5 0-1 45 Unruptured AVMs
Potts et al. (2015)118 1.7 0-1 232 SMG I-II AVMs
Han et al. (2015)86 1.3 0-2 27 Brainstem AVMs
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6 DISCUSSION
6.1 The long-term HRQoL 
in AVM patients in 
general is favorable
After severe illness, it is not self-evident 
that the patient can return to the pre-
morbid lifestyle or adjust to the changes 
in the postmorbid condition. This is 
especially true for the young, working-age 
AVM patients, who are usually without 
pre-existing comorbidities during their 
diagnosis. Taking these factors into 
consideration, after long-term follow-up 
the HRQoL results in general were only 
modestly impaired when compared to 
the general population.I,III Interestingly, 
certain subgroups, such as mRS 0 AVM 
patients had even better subjective 
HRQoL than the general population 
controls.III The factors associated with 
decreased HRQoL in the multivariate 
model were older age, sex (female), 
refractory epilepsy, SPC C type lesion 
and more than one bleeding episode.I 
Also, understandably, poor functional 
status decreased the HRQoL in long-
term follow-up.I,III The decrease in 
the ability to continue previous usual 
activities was a major component 
explaining the impaired HRQoL.I,III This 
dimension is one of the key elements 
creating postmorbid happiness and 
life satisfaction.230, 242 Despite this, only 
a few had had to retire from their 
work owing to the AVM, illustrating 
at least some capability to continue 
the previous lifestyle.I Return to work 
is a well-recognized component of 
postmorbid QoL and life satisfaction in 
patients with SAH and ICH.230, 243 Mental 
functioning, another important factor 
affecting postmorbid HRQoL,228, 229 was 
impaired only in patients with refractory, 
symptomatic epilepsy and SPC C 
lesions.I This decrease has previously 
been explained with possible damage 
to the reticular formation and related 
structures of the brain controlling arousal, 
and it has been associated with sleeping 
disorders, stress, pain and chronic 
illnesses in SAH and IS patients.230, 231 
However, given the decrease epilepsy 
has on HRQoL independently based 
on previous studies,58 it is possible that 
the anticonvulsive medicine and factors 
related to the epilepsy itself affect the 
HRQoL substantially more than these 
theoretical changes in the parenchyma 
owing to AVM hemorrhage. However, 
the magnitude in which these factors 
independently affect postmorbid HRQoL 
cannot be differentiated by our results.
6.2 Treatment decisions
ARUBA managed to turn the 
treatment policies of AVM patients 
into a more conservative course. It has 
sparked vigorous conversation in the 
neurosurgical community about the 
risks of interventional treatment, and 
on the other hand the risks of watchful 
waiting. SPC B patients have been the 
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borderline group regarding treatment 
recommendations. According to our 
results, the long-term HRQoL was 
relatively similar between SPC A (who 
are generally considered safe for surgery) 
and SPC B patients.I Taking into account 
the effect multiple bleeding episodes had 
on HRQoL, our results carefully suggest 
that interventional treatment can yield 
as successful results in SPC B patients 
as in SPC A patients.I Direct treatment 
recommendations cannot be given, 
however, without a conservative control 
group. Furthermore, the variability of 
lesion anatomy inside the SPC B category 
should be considered. Therefore, the 
importance of careful evaluation of 
treatment possibilities in light of the 
features of the AVM, preferably by an 
interdisciplinary team, is extenuated 
in this patient group. Our long-term 
HRQoL results do not question the role 
of microsurgery as the gold standard 
for SPC A patients. However, mirroring 
the decreased HRQoL of treated SPC C 
patients, it is still advisable to remain 
conservative at least until progressive 
neurological symptoms begin to develop 
or the lesion bleeds. Again, without a 
control group, we cannot tell what the 
HRQoL of these patients would have been 
with a conservative treatment policy. The 
survival bias associated with our long 
follow-up time could optimize the results 
for these patients, as well as the other 
groups included in our studies. There 
was a significant decrease of HRQoL in 
the patients with symptomatic refractory 
epilepsy (Engel II–IV).I Therefore, 
complete seizure-freedom also creates 
another meaningful treatment goal in 
the sense of postoperative HRQoL. 
6.3 Dichotomous mRS 
The subjectivity of ‘’good’’ and ‘’bad’’ 
creates difficulties in the analysis, 
reporting and interpretation of outcome. 
Some minor postoperative symptoms 
might be accepted if the patient was 
doing worse off preoperatively, whereas, 
for an asymptomatic patient the same 
symptoms might represent a significant 
decrease in HRQoL. Objective outcome 
instruments, such as mRS, are needed in 
the transparent comparison of treatment 
strategies, patients and institutions. As 
an objective outcome instrument, this 
phenomenon based on subjectivity 
should not affect the evaluation of the 
mRS. However, with an increasing 
interest in HRQoL, and the increased 
use of utility-weighted mRS in the 
scientific community, we wanted to 
explore the interconnected relationship 
of the objective mRS and the subjective 
HRQoL measured with 15D. Given that 
mRS is meant to demonstrate the ability 
to continue previous usual activities and 
functional in/dependence, these factors 
were translated into the subjective 
HRQoL, with the exception of overlap 
between mRS 1 and mRS 2 patients in the 
dimension of usual activities.III Despite 
this connection between objective and 
subjective outcome, the determining of 
unfavorable and favorable mRS remains 
difficult because many aspects of HRQoL 
were not illustrated by mRS.III The 
psychological and mental dimensions, 
major components of life satisfaction, 
were not differentiated between the 
grades.III In contrast, differences in these 
dimensions were demonstrated in the first 
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study of this thesis, suggesting that this 
was not owing to the inability of the 15D to 
capture the differences.I This is one of the 
many reasons why the arbitrary division 
of mRS into ‘’good’’ and ‘’bad’’ should be 
avoided. Furthermore, since in real life 
we are interested in the improvement or 
decline of a patient’s condition, should not 
the methodology be set so that it could 
capture these movements across the scale? 
6.4 Differences between AVM 
patients in mRS 0 and 1
Dichotomizing has been and is 
still common in neurological and 
neurosurgical research. Therefore, 
understanding the effect it has on 
research results is essential. With our 
literature review, we illustrated that the 
two most common cut points used in 
the recent neurosurgical literature are 
between mRS 1 and 2, and 2 and 3.III 
Both of these options have also been 
the common alternatives in many stroke 
trials and neurological research. Our 
results that mRS 0 and mRS 1 have a 
significantly different long-term HRQoL, 
and on the other hand that mRS 1 and 2 
patients had a relatively similar HRQoL, 
clash against the inclusion of mRS 0 
and 1 patients into the same category of 
‘’favorable’’ outcome.III However, these 
results are against the recent findings 
of two meta-analyses using the EQ-5D 
HRQoL instrument, in which mRS 0 and 
mRS 1 stroke patients were regarded as 
close in utility weights.244, 245 Compared 
to 15D, EQ-5D has been reported to have 
a higher ceiling effect, meaning that the 
improvement in HRQoL with patients 
in the best possible health states might 
remain undetected because the scale 
runs out.246 Also, the aforementioned 
meta-analyses have investigated mostly 
IS patients. The different biology behind 
the diseases could explain why, despite 
being classified similarly in regard to 
functioning, the rest of the dimensions 
differ significantly. 
So based on our results, it seems that 
the inclusion of mRS 0 and mRS 1 in 
the same category might overly optimize 
the results for mRS 1 patients in AVM 
research.III Additionally, dichotomizing 
between mRS 1 and 2 creates an artificial 
boundary between the patients, when in 
fact they seem to be close in long-term 
HRQoL.III Whether these findings apply 
to other causes of ICH is a subject for 
future research. Some of the extreme 
improvement in the HRQoL of mRS 0 
patients compared to the general population 
might be explained by the fact that it could 
be difficult for the control individuals to 
estimate their common symptomatology 
compared to patients who have possibly 
experienced real disabling symptoms. 
However, this same phenomenon also 
exists with the control individuals in the 
mRS 1 comparison, and thus does not 
explain the difference between mRS 0 
and mRS 1 patients. 
Even if we got rid of mRS 
dichotomization in future research, it 
should be noted that the gaps between 
mRS grades are not identical in distance, 
meaning that a drop in functional outcome 
from mRS 1 to mRS 2 does not change the 
HRQoL as much as the drop from mRS 
0 to mRS 1. Furthermore, in real life the 
starting point of the patient plays a major 
role in the interpretation of the outcome, 
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since for an asymptomatic patient with an 
unruptured lesion the outcome of mRS 
1 might be a catastrophe, whereas for an 
unconscious patient after a massive AVM 
hemorrhage the same outcome could be 
regarded as phenomenal. Further analyses 
of these different scenarios are needed, 
as well as results from other patient 
populations to widen our understanding 
of the mRS and to improve our future 
research.
6.5 The prevalence of 
smokers in AVM patients 
Researchers have long suggested the two-
hit theory behind the formation of AVMs.44 
Yet, no external pathogens had reliably 
been linked to AVM patients before our 
findings.II Neither the causality nor the 
exact relationship between smoking and 
AVM patients can be discovered by our 
results, however, the high prevalence of 
smokers during the diagnosis of AVM 
could suggest a role in either provoking 
the rupture or behind the etiology. It 
is safe to say that smoking cessation 
should be recommended to all patients 
with cerebrovascular diseases, including 
AVM patients. This is also supported by 
the finding that smoking can decrease 
the likelihood of AVM obliteration.185 
Whether the trend of less smoking in 
the 2000s and presumably in the future 
decreases the rupture rates is another 
interesting topic of future research. 
There has already been a slight decrease 
in the incidence of new AVMs in our 
clinic, however, the exact trend will only 
be illustrated during the years to come. 
It is possible, given the interconnected 
relationship of many notorious lifestyle 
factors, that there are other modifiable 
risk factors yet to be discovered. Another 
well-known cerebrovascular risk factor, 
hypertension, was linked to hemorrhagic 
presentation of AVM patients already in 
1998,182 however, these results have not 
been replicated in other patient cohorts 
ever since. Whether this is owing to 
the difficulty in the methodologies 
or the lack of underlying connection 
between AVM patients and hypertension, 
cannot be determined based on current 
knowledge. We hope our findings spark 
the exploration of AVM patient cohorts, 
since the confirmation of this connection 
between smoking and AVM patients 
could be the key factor in determining 
the etiology and future treatment of 
AVMs.
6.6 Future aspects
The on-going exploration of AVM 
pathogenesis opens up new possibilities 
for novel medical therapies. The 
connection we found between AVM 
patients and smoking is well-suited to 
these theories about the importance of 
VEGF and other vascular endothelial 
markers in the pathogenesis of AVMS.
II Even before the finding of KRAS 
mutations in somatic AVMs,7 there 
have been few phase 1 trials on the 
pharmaceutical possibilities in treating 
AVM patients. Anti-VEGF drugs have 
been proposed as a future treatment. 
There is one phase 1 clinical trial 
(NCT02314377) investigating the safety 
and effectiveness of bevacizumab 
(VEGF-A inhibitor), which ended in 
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December 2019, however, results are yet 
unpublished. The tetracycline derivates 
such as minocycline and doxycycline 
(MMP-9 inhibitors) have also been 
investigated and deemed feasible in 
phase 1 for future trials.247 A phase 
2 trial (NCT04297033) investigating 
lovastatin is currently on-going and is 
estimated to be completed in 2024. The 
mechanism of action is proposed to be 
in the stabilizing, anti-inflammatory and 
antiproliferative, effect of statins on the 
endothelium. These medical therapies 
are of special importance to those patients 
currently out of possibilities regarding 
interventional methods. However, given 
the majority of patients are diagnosed 
with already ruptured AVMs, the need 
for interventional methods is not likely 
to be diminishing in the near future. 
Therefore, discovering the risk factors 
behind AVM formation and in this 
way catching these lesions before they 
rupture is the next major challenge in 
AVM research.
Studies on the HRQoL of AVM 
patients will help clinicians together with 
the patients contemplate the risks of 
interventional treatment methods against 
the risks of conservative management. 
Understanding the outcome in more 
detail than just the functionality or 
independence will help focus resources 
on the aspects needing rehabilitation or 
intervention. There is a new on-going 
clinical trial for the treatment of brain 
AVMs (TOBAS, NCT02098252), however, 
it has not reported a HRQoL outcome nor 
as a primary nor secondary outcome. Still, 
its results will help in understanding the 
results of ARUBA, however, it will take 
many years still to complete. Until then, 
understanding HRQoL will give us new 
information about AVM patients and 
therefore becomes especially important in 
the discussion about treatment strategies. 
Finland is well-suited for epidemio-
logical studies owing to its nation-wide 
registries and public healthcare system, 
in which all AVM patients are treated in 
university hospitals. An interesting idea 
for future research would be to use these 
national healthcare registries to track the 
condition of the patients who did not 
answer the HRQoL questionnaire sent in 
2016. To apply this even further, a nation-
wide AVM registry could be collected using 
the data derived from the Finnish Institute 
for Health and Welfare (THL), Kela (social 
insurance institution) and the Kanta 
(social and healthcare services) registries. 
These systems allow researchers access 
to electronic prescriptions, rehabilitation 
benefits and disability pension data, in 
addition to numerous other important 
factors in understanding the comorbidities, 
lifestyle, functional outcome and QoL of 
AVM patients.
6.7 Limitations
The long follow-up time causes at least 
some magnitude of survival bias, which 
optimizes our results by excluding those 
not well enough to answer or to survive 
long enough to attend the survey. This 
has to be considered, especially with the 
patients with the SPC C lesions, multiple 
bleeding episodes and deeply located 
AVMs. Additionally, owing to the small 
number of patients treated with either 
only embolization or SRS, comparisons 
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between treatment modalities could not 
be conducted. 
Study II was limited by its cross-
sectional nature, as this design of study 
cannot prove causality. Also, many AVM 
patients had left some parts of the HRQoL 
questionnaire unanswered, which led 
to classifying them as nonsmokers to 
obtain a conservative estimate about the 
prevalence of smokers. Therefore, the 
real prevalence could be higher than we 
reported. On the other hand, smoking 
was common in the previous millennium, 
which might cause overestimation, 
however, this was taken into account by 
controlling for the general population 
with age group, sex and admission year. 
Finally, owing to the relative homogeneity 
of the Finnish population, our results are 
not generalizable to other nationalities. 
Therefore, we encourage other research 
groups to study their patient populations 




The research papers of this thesis 
project reported novel findings about 
the risk factors for decreased HRQoL 
in long-term follow-up, the possible 
underlying lifestyle risk factors of AVM 
patients and the methodological risks the 
common use of mRS dichotomization 
might pose. In the post-ARUBA era, our 
results were able to support the active 
treatment of selected SPC B patients by 
showing favorable HRQoL outcomes 
after a total obliteration of the AVM 
and to remain conservative with SPC C 
patients. The HRQoL results illustrated 
that there is room for improvement 
regarding the postoperative treatment 
of AVM patients, as many of them 
suffer from impairments of mental 
health and decreased ability to continue 
previous activities, even decades after the 
incidence. Still, the overall outcome of 
AVM patients was rather favorable, when 
considering the severity of the disease 
and the outcomes of the patients with 
other causes of intracranial hemorrhage. 
The finding of the association between 
cigarette smoking and AVM patients 
inspires more vigorous investigation of 
the currently unknown etiology of AVMs. 
Understanding the etiology could open 
up new possibilities for prevention and 
medical therapies in AVM treatment. 
Finally, our results revealed that the 
dichotomous analysis of the mRS in the 
outcome analyses should be critically re-
evaluated, as there could be considerable 
differences in the postoperative outcomes 
of mRS 0 and mRS 1 patients. None of 
these findings were possible without 
the application of the patient-reported 
outcome evaluation, the use of modern 
HRQoL instruments and the help of my 
instructors and co-writers.  
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Appendix 1: The 15D questionnaire. Patients are asked to fill 
in the option that best describes their current health status.
QUESTION 1. MOBILITY
1 ( ) I am able to walk normally (without difficulty) indoors, outdoors and on stairs.
2 ( ) I am able to walk without difficulty indoors, but outdoors and/or on stairs I have slight difficulties.
3 ( ) I am able to walk without help indoors (with or without an appliance), but outdoors and/or on stairs only with considerable difficulty or with help from others.
4 ( ) I am able to walk indoors only with help from others.
5 ( ) I am completely bed-ridden and unable to move about.
QUESTION 2. VISION 
1 ( ) I see normally, i.e. I can read newspapers and TV text without difficulty  (with or without glasses).
2 ( ) I can read papers and/or TV text with slight difficulty (with or without glasses).
3 ( ) I can read papers and/or TV text with considerable difficulty  (with or without glasses).
4 ( ) I cannot read papers or TV text either with glasses or without, but I can see enough to walk about without guidance.
5 ( ) I cannot see enough to walk about without a guide, i.e. I am almost or completely blind.
QUESTION 3. HEARING
1 ( ) I can hear normally, i.e. normal speech (with or without a hearing aid).
2 ( ) I hear normal speech with a little difficulty.
3 ( ) I hear normal speech with considerable difficulty; in conversation I need voices to be louder than normal.
4 ( ) I hear even loud voices poorly; I am almost deaf.
5 ( ) I am completely deaf.
QUESTION 4. BREATHING 
1 ( ) I am able to breathe normally, i.e. with no shortness of breath or other breathing difficulty.
2 ( ) I have shortness of breath during heavy work or sports, or when walking briskly on flat ground or slightly uphill.
3 ( ) I have shortness of breath when walking on flat ground at the same speed as others my age.
4 ( ) I get shortness of breath even after light activity, e.g. washing or dressing myself.




1 ( ) I am able to sleep normally, i.e. I have no problems with sleeping.
2 ( ) I have slight problems with sleeping, e.g. difficulty in falling asleep, or sometimes waking at night.
3 ( ) I have moderate problems with sleeping, e.g. disturbed sleep, or feeling I have not slept enough.
4 ( ) I have great problems with sleeping, e.g. having to use sleeping pills often or routinely, or usually waking at night and/or too early in the morning.
5 ( ) I suffer severe sleeplessness, e.g. sleep is almost impossible even with full use of sleeping pills, or staying awake most of the night.
QUESTION 6. EATING 
1 ( ) I am able to eat normally, i.e. with no help from others.
2 ( ) I am able to eat by myself with minor difficulty (e.g. slowly, clumsily, shakily, or with special appliances).
3 ( ) I need some help from another person in eating.
4 ( ) I am unable to eat by myself at all, so I must be fed by another person.
5 ( ) I am unable to eat at all, so I am fed either by tube or intravenously.
QUESTION 7. SPEECH 
1 ( ) I am able to speak normally, i.e. clearly, audibly and fluently.
2 ( ) I have slight speech difficulties, e.g. occasional fumbling for words, mumbling, or changes of pitch.
3 ( ) I can make myself understood, but my speech is e.g. disjointed, faltering, stuttering or stammering.
4 ( ) Most people have great difficulty understanding my speech.
5 ( ) I can only make myself understood by gestures.
QUESTION 8. EXCRETION 
1 ( ) My bladder and bowel work normally and without problems.
2 ( ) I have slight problems with my bladder and/or bowel function, e.g. difficulties with urination, or loose or hard bowels.
3 ( ) I have marked problems with my bladder and/or bowel function, e.g. occasional ’accidents’, or severe constipation or diarrhea.
4 ( ) I have serious problems with my bladder and/or bowel function, e.g. routine ’accidents’, or need of catheterization or enemas.
5 ( ) I have no control over my bladder and/or bowel function.
QUESTION 9. USUAL ACTIVITIES 
1 ( ) I am able to perform my usual activities (e.g. employment, studying, housework, free- time activities) without difficulty.
2 ( ) I am able to perform my usual activities slightly less effectively or with minor difficulty.
3 ( ) I am able to perform my usual activities much less effectively, with considerable difficulty, or not completely.
4 ( ) I can only manage a small proportion of my previously usual activities.
5 ( ) I am unable to manage any of my previously usual activities. 
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QUESTION 10. MENTAL FUNCTION 
1 ( ) I am able to think clearly and logically, and my memory functions well
2 ( ) I have slight difficulties in thinking clearly and logically, or my memory sometimes fails me.
3 ( ) I have marked difficulties in thinking clearly and logically, or my memory is somewhat impaired.
4 ( ) I have great difficulties in thinking clearly and logically, or my memory is seriously impaired.
5 ( ) I am permanently confused and disoriented in place and time.
QUESTION 11. DISCOMFORT AND SYMPTOMS 
1 ( ) I have no physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc.
2 ( ) I have mild physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc.
3 ( ) I have marked physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc.
4 ( ) I have severe physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc.
5 ( ) I have unbearable physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc.
QUESTION 12. DEPRESSION 
1 ( ) I do not feel at all sad, melancholic or depressed.
2 ( ) I feel slightly sad, melancholic or depressed.
3 ( ) I feel moderately sad, melancholic or depressed.
4 ( ) I feel very sad, melancholic or depressed.
5 ( ) I feel extremely sad, melancholic or depressed.
QUESTION 13. DISTRESS 
1 ( ) I do not feel at all anxious, stressed or nervous.
2 ( ) I feel slightly anxious, stressed or nervous.
3 ( ) I feel moderately anxious, stressed or nervous.
4 ( ) I feel very anxious, stressed or nervous.
5 ( ) I feel extremely anxious, stressed or nervous.
QUESTION 14. VITALITY 
1 ( ) I feel healthy and energetic.
2 ( ) I feel slightly weary, tired or feeble.
3 ( ) I feel moderately weary, tired or feeble.
4 ( ) I feel very weary, tired or feeble, almost exhausted.
5 ( ) I feel extremely weary, tired or feeble, totally exhausted. 
QUESTION 15. SEXUAL ACTIVITY 
1 ( ) My state of health has no adverse effect on my sexual activity.
2 ( ) My state of health has a slight effect on my sexual activity.
3 ( ) My state of health has a considerable effect on my sexual activity.
4 ( ) My state of health makes sexual activity almost impossible.
5 ( ) My state of health makes sexual activity impossible.
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